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CHAPTER 1 
IRON 
 
IRON HOMEOSTASIS 
Iron is an element necessary for all the organisms for life; its role in essential 
metabolism, cellular processes, energy production, biosynthesis is well described. 
Although being so important, it has damaging properties in its free form. Its capacity to 
change between the +2 and +3 oxidation states, may produce reactive oxygen species 
(ROS) responsible for cellular and tissue damage. In order to neutralize those negative 
effects iron need to be associated with proteins: in the plasma is mainly coupled with 
transferrin; in the cell is linked to chaperones or storage within ferritin. In mammals, 
heme synthesis during erythropoiesis requires the highest amount of iron; erythrocytes, 
fundamental for their role in respiration, are mostly constituted of haemoglobin (4 
heme group/Hb), erythrophagocytosis, mediated by macrophages, remove senescent 
erythrocytes from circulation and makes iron newly reusable. Iron homeostasis is 
finely regulated at different level and with different protagonists: enterocytes absorb 
iron from food, macrophages recycle iron derived from erythrocytes destruction, 
hepatocytes are the principal storage of iron. Hepcidin, a liver hormone, plays a key 
role in the process; its transcription is up-regulated by high iron levels, infection and 
inflammation, on the other hand down regulated by anemia and erythropoiesis. 
Hepcidin binds the iron exporter (unique in all the cells and organisms) ferroportin-1 
(Fpn1) at the cell surface causing its internalization and degradation. Moreover the iron 
homeostasis is localized also at cellular level to regulate the expression of genes related 
to iron metabolism. Iron regulatory protein (IRP)/iron responsive element (IRE) system 
controls both mRNA stability and translation of proteins involved in iron homeostasis 
[1].  
 
HUMAN IRON METABOLISM  
In the human body iron is present as ferrous (Fe
2+
) and ferric (Fe
3+
) iron [2]. Fe
3+
 is the 
most stable ion with physiological concentration of oxygen. Fe
2+
 reduces O2 with the 
formation of superoxide radicals [3]. The presence of ROS is responsible for damaging 
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proteins, nucleic acids and carbohydrates, and for starting lipid peroxidation and, 
lastly, cellular apoptosis [4]. Thus, is important for iron metabolism prevent the 
formation of free iron. All mechanisms, involved in this process, comprehend iron 
absorption in the gut, transport via circulation, cellular intake and utilization, 
macrophagic recycle and liver storage [5,6] (Figure 1).  
Absorption 
Iron derived from food is heme iron or non-heme iron [7]; the first is present in meat as 
haemoglobin and myoglobin. Heme release from hemo proteins is due to the low pH of 
the stomach combined to proteolytic enzymes. Heme uptake in enterocyte is mediated 
by the heme-carrier protein 1 (HCP1), together with the proton coupled folate 
transporter (PCFT) (Figure 1A); the latter has low-affinity to heme and is more 
involved in folate absorption [8]. Inside the cell heme oxygenase 1 (HO1) breaks heme 
and release Fe
3+
. Non-heme iron is mainly Fe
3+
; acid pH of the stomach and ascorbic 
acid reduce Fe
3+
 to Fe
2+
 to permit the uptake in the enterocyte [7]. Apical membrane of 
enterocyte presents on its surface all the proteins necessary for iron absorption. In 
particular proteins for iron reduction, such as duodenal cytochrome b (DcytB) and six 
transmembrane epithelial antigen of the prostate 2 (Steap2) [9,10], and for iron uptake 
in the cell, the proton-coupled divalent metal transporter 1 (DMT1) (Figure 1A). 
DMT1 is involved in the absorption of different divalent metal ions (iron, cobalt, 
manganese, zinc, cadmium and others); it is a transmembrane protein that perform the 
symport of Fe
2+
 coupled with H
+
 , utilizing the proton gradient between the gut lumen 
and the enterocyte cytoplasm [11]. Inside the cell iron is addressed to the basolateral 
membrane to be exported or stored in ferritin. It is notable that, in mice, the absence of 
the IRE/IRP system increases ferritin levels, iron is blocked in the enterocyte, 
independently of the iron status of the organism [12]. The access of iron in the whole 
body with circulation depend on the export of iron from the enterocyte; Fpn1 is 
expressed at basolateral membrane of enterocyte, is the only mammal iron exporter 
[13]; Fpn1 transports Fe
2+
 outside the basolateral membrane where ferroxidases, 
hephaestin (Heph) and ceruloplasmin (Cp) oxidize Fe
2+
 to Fe
3+
 to be associated with 
transferrin (Tf) in circulation [14,15] (Figure 1A). 
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Transport and cellular uptake 
After absorption iron is distributed in the organism conjugated with transferrin. The 
oxidation state, the protein conformation and pH influence the stability of transferrin-
bound iron (TBI). Tf could be found in the plasma in three different forms: apo-
transferrin (apo-Tf), protein without iron; monoferric transferrin (with a single iron 
atom); and diferric transferrin or holotransferrin (holo-Tf; with two iron atoms) [16]. 
The acute need of iron is regulated with the presence of these three states of Tf 
avoiding the negative effects of iron excess in the organism. Transferrin receptor1 
(TfR1), located in cell membrane, is responsible for cellular uptake of TBI [17]. Next 
step is a clathrin-dependent endocytosis of the TBI–TfR1 complex. The intake of H+ 
by an ATP-dependent proton pump acidifies the endosome causing the release of Fe
3+
, 
while apo-Tf remains complexed with TfR1. In the endosome, Fe
3+ 
is converted by 
Steap 3 to Fe
2+
and transported by DMT1 in the cytoplasm [11,18]. At the same time, 
the Tf–TfR1 complex return to the cell membrane where apo-Tf return in the 
circulation (Figure 1B). Exists also a non-transferrin bound iron (NTBI) form detected 
in the plasma [19]. Mainly NTBI is Fe
3+
 bound to citrate or acetate [20]; this different 
iron is mainly directed to hepatocytes where the zinc transporter Zrt–Irt-like protein 14 
(Zip 14) [21] mediates the uptake with an endocytosis-independent mechanism.  
Consumption and storage 
Synthesis of haemoglobin in the erythroblasts is the principal cause of high iron 
necessity. Heme iron in erythrocytes corresponds to 70% of the body iron pool [22]. 
Iron released from endosome is conducted to mitochondrion, the principal organelle 
responsible for cellular iron homeostasis. Iron is driven to mitochondria by a cytosolic 
iron chaperon, the poly (rC) binding protein 1 (PCBP1) [23], or directly from the 
endosome with a ‘kiss-and-run’ mechanism (seen in immature erythrocyte where 
haemoglobin synthesis is higher) [24]; in mitochondria iron is fundamental for 
biosynthesis of heme. Beyond iron utilization in biosynthesis, iron storage is also 
important to avoid the presence of free iron or to provide rapid accessibility during iron 
deficiency. Principal contributor in iron storage is the ferritin (Ft) protein [25] (Figure 
1C). Ferritin is a 24-subunit multimer of heavy (Ft-H) and light (Ft-L) polypeptide 
chains; after synthesis, these chains self-assemble in a spherical structure that is able to 
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incorporate up to 4500 iron atoms inside. PCBP chaperones drive cytosolic Fe
2+ 
 to Ft, 
Ft-H subunit oxidizes Fe
2+ 
 to Fe
3+ 
, Ft-L subunit is responsible for its uptake into the 
core [23]. Ft is in the cytosol, nucleus and mitochondria, but is also present in the 
serum (sFt). Mitochondria present their own Ft-H-like chains; in particular, the 
mitochondrial Ft (mFt) is more efficient than the cytoplasmic one to store iron [26]. 
The iron release from Ft is mediated by lysosome and proteasome degradation [27,28]. 
The nuclear receptor coactivator 4 (NCOA4) is a cargo receptor that binds and carry Ft 
in lysosomes, regulating iron bioavailability [29]. Accordingly, NCOA4 expression is 
up-regulated during erythropoiesis-a process with high necessity of iron-[30]. 
Ncoa4−/− mice showed a severe iron overload in splenic macrophages-responsible of 
iron recycle in senescent erythrocytes- suggesting the importance of NCOA4 in iron 
equilibrium [31]. 
Recycling  
Splenic and hepatic macrophages scavenges senescent erythrocytes to obtain iron from 
haemoglobin ready to be reutilized in the synthesis of new molecules of haemoglobin 
[32] (Figure 1D). Macrophages are able to detect markers of aging on erythrocyte 
membranes [33-36]; in particular: alteration in the erythrocyte solute carrier family 4 
(anion exchanger) member 1 (SLC4A1), the presence of membrane 
phosphatidylserine, and the decrease of membrane flexibility, sialic acid and in CD47 
antigen. All these modifications elicit erythrocyte phagocytosis macrophage mediated; 
in the phagolysosome, ROS and hydrolytic enzymes cause the release of heme from 
erythrocyte to the vacuolar fluid. Then, HO1 together with O2 split heme in iron, CO 
and biliverdin [37]. Intravascular hemolysis causes the release of haemoglobin in 
circulation, where it is conjugated with haptoglobin; this protein is recognized by 
CD163, membrane macrophage receptor [38] (Figure 1D). The transport of iron within 
the macrophage comprehend: (a) phagosome membrane transport mediated by DMT1 
transporter and the natural resistance-associated macrophage protein (Nramp1) [39]; 
(b) movement in the cytoplasm with PCBP chaperones [31]; and (c) Fpn1 for the 
release of Fe
2+
 outside the cell where the enzyme glycosylphosphatidylinositol-linked 
(Gpi)-ceruloplasmin oxidizes Fe
2+
 to Fe
3+
 and allows the binding of Fe
3+
 to serum Tf 
[40]. 
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REGULATION OF IRON METABOLISM 
Iron homeostasis in human organism is committed to several mechanisms: control of 
iron absorption, recycling and storage. Given that there are no mechanisms for iron 
excretion, only 1 mg of dietary iron every day is needed. This process exceeds the non 
specific iron losses caused by bleeding, sweat and sloughing of epithelial cells. The 
increased need of iron involves augmented duodenal absorption and release from 
macrophages and from storage cells (mainly epatocytes). On the other hand, iron 
overload induces the inhibition of absorption and increases storage, to avoid toxic 
effects of excessive free iron [41,42]. Iron homeostasis is finely regulated at systemic 
and cellular level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Systemic iron metabolism regulation. The maintenance of iron homeostasis 
includes the regulation of (A) dietary iron by duodenum enterocyte, (B) usage by erythroblasts, 
(C) storage by hepatocytes and (D) recycling by splenic macrophages. After being reduced by 
ascorbic acid and Dcytb at the apical membrane of enterocytes, iron is absorbed by DMT1 and 
driven to the basolateral membrane of these cells where it is exported by Fpn1 to circulation 
associated with transferrin (holo-Tf). Erythrocytes, which require the major amounts of iron, 
capture holo-Tf through the membrane-associated TfR1. After being endocytosed, iron is used 
by mitochondria for heme synthesis. If iron absorbed is more than required, it is stored in 
ferritin, mostly in hepatocytes. The most common source of iron are macrophages, as they 
phagocyte the senescent erythrocytes, releasing iron from heme through the HO1, rendering it 
available to be reutilized by the cells. In the control of all of these processes there is hepcidin, a 
circulatory protein synthesized in the liver accordingly to iron levels. Hepcidin acts by binding 
membrane-associated Fpn1, inducing its internalization and degradation and, consequently, 
preventing dietary iron absorption and release from storing hepatocytes and recycling 
macrophages. Modified from [1]. 
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Systemic regulation 
The principal regulator of iron homeostasis is hepcidin, it is a hormone peptide of 25 
amino acid mainly synthesized in the liver [43]. Many physiological conditions play a 
role in hepcidin expression: systemic iron levels, hypoxia, anemia, erythropoiesis, 
infection and inflammation [44-46] (Figure 1C). HAMP gene on chromosome 19 
encodes for hepcidin protein. The synthesis starts with an inactive pre-pro-protein of 
84 aa-with signal peptide, pro-region and the active sequence of 25 aa [47]. In cell 
hepcidin becomes mature via a proteolytic cleavage due to the prohormone convertase 
furin [48]. Hepcidin promotes Fpn1 internalization and, consequent degradation [49] 
(Figure 1). The mechanism of internalization involves a rapid ubiquitination of Fpn1 
[50]. Thank to this mechanism, hepcidin controls dietary iron uptake and release from 
macrophages, hepatocytes and other cells involved in systemic iron metabolism. 
HAMP expression is induced by iron overload, infection and inflammation [44,49,51], 
whereas reduced by iron deficiency, hypoxia, anemia and erythropoiesis [45,46] 
(Figure 2).  
Iron levels 
Iron level permits the regulation of HAMP expression, avoiding toxic effects of iron 
overload or negative consequences of iron deficiency. Hepatocytes showed different 
proteins on its membranes named “iron sensors”: hemojuvelin (Hjv), HFE, TfR1, and 
TfR2 [1]. Hjv-bone morphogenetic protein (BMP) axis controls HAMP expression 
principally in the liver [54]. Hjv is the co-receptor of BMPs-cytokines belonging to the 
transforming growth factor β superfamily [55]. The binding of BMP to Hjv and BMP 
activates phosphorylation of cytosolic SMADs 1, 5 and 8 [54,56,57]. Consequently, 
the transcription of HAMP gene is induced by phosphorylated SMADs bind to 
SMAD4, that in nucleus interact with BMP responsive elements (BMPREs) at HAMP 
promoter [58,59]. Moreover the membrane proteins HFE and TfR2 could regulate 
hepcidin expression in response to iron levels (Figure 2). Under iron homeostatic 
conditions, TfR1 binds HFE on epatocyte cell surface [60]. TfR1 binds also iron 
loaded transferrin (Fe2-Tf) with a higher affinity; the overlapping binding site for HFE 
and Fe2-Tf,if iron plasma levels increase, causes the dissociation of HFE from TfR1 
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that consequently could bind TfR2 [51,61] with the final effect of trigger HAMP 
expression [62].  
Figure 2. Mechanisms regulating iron metabolism in the cell. ZIP family transporters, ZIP8 
and ZIP14, are fundamental for transporting NTBI after reduction of NTBI by prion protein 
(PRNP). In the acidic endosome, Fe
3+
 is released from Tf and free Fe
3+
 is reduced to Fe
2+
 by 
STEAP3 and transported to the cytoplasm by divalent DMT1 and ZIP8/14. PCBP1 and PCBP2 
are cytosolic iron chaperones that deliver Fe
2+
 to apo-proteins, such HIF (prolyl hydroxylases), 
ferroportin (iron export), and ferritin (oxidation to Fe
3+
, storage). NCOA4 mediated autophagy 
of iron loaded ferritin with the release of iron for utilization in cellular processes. Modified 
from Bogdan 2016 [53]. 
 
Infection and inflammation 
All organisms, pathogens included, need iron for survival and proliferation. During 
infection, pathogens utilize the iron pool of the host. The immune system responds to 
pathogen with several innate and adaptive mechanisms, among these hypoferremia has 
a host defence function [49]. During infection, the iron concentration in the plasma 
may decrease from the physiological range of 10-30 μM to 1-3 μM [63]; also at lower 
concentration iron is strongly bound to Tf, inaccessible to pathogen iron transporters, 
limiting the generation of NTBI that can be promptly used by many microorganisms 
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[63]. Hepcidin promotes all mechanisms responsible for hypoferremia during 
inflammation and infection [64]. In fact hepcidin levels are greatly increased during 
infection and inflammation [63]; due to hepcidin increase, Fpn1 endocytosis and 
degradation promotes low iron absorption from diet and high deposition of iron in 
macrophage and storing cells [1]. In particular, increased iron scavenging and 
macrophage storage play a key role in evading iron to pathogens and protecting the 
host from the toxic effects of increased levels of iron, heme and hemoglobin that could 
result from tissue damage during infection and inflammation [63]. The presence of 
pathogens during infection induce macrophage and other cell type to recognize “non 
self” and to induce the secretion of pro-inflammatory cytokines, as interleukin (IL)-6, -
22 and type-1 interferon (IFN) [49,64-66]. All these cytokines trigger the expression of 
HAMP gene, in particular binding TLR on the membranes of hepatocytes and 
leukocytes and stimulating Jak-signal transducer and Stat3 pathway [67]. Thus 
extracellular pathogens are deprived of iron. 
Moreover innate immunity engages also other proteins than hepcidin able to relocate 
and sequester iron useful for host defence [63]. In particular lactoferrin, an homologue 
of Tf that differs for the capacity to bind iron also at low pH, a typical milieu of 
inflamed and infected tissues; haptoglobin transports free Hb, hemopexin transports 
heme to macrophages and hepatocytes for degradation. Nramp1 is an iron transporter 
of Fe
2+ 
found on membranes of phagocytic vacuoles of macrophages and neutrophils 
[63]. All these proteins, involved with iron binding or transport, show an increased 
expression during infection and inflammation; their synthesis is cytokines induced (i.e. 
Nramp1 is induced by LPS and IFNγ) [68]. 
Hypoxia 
Red blood cells and, consequently, the O2 transporter hemoglobin are produced via 
erythropoiesis. During hypoxia, low body oxygen levels induce erythropoiesis. Iron 
metabolism and erythropoiesis during hypoxia are modulated by hypoxia inducing 
factor (HIF) [69] (Figure 2). HIFs are transcription factors that bind hypoxia-response 
elements (HREs), controlling the expression of Tf, TfR1, and CP, as well as of 
HMOX, SLC11A2, CYBRD1 and EPO (the genes responsible for the expression of 
HO1, DMT1, DcytB and erythropoietin, respectively) resulting in enhanced intestinal 
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iron uptake, inhibition of HAMP expression in the liver, through a HRE-mediated 
mechanism [70-73].  
Anemia and erythropoiesis 
Ineffective erythropoiesis mimics a hypoxic condition observed during anemia. 
Erythropoietin (Epo) is a glycoprotein hormone mainly synthesized in the adult kidney 
[74]. Its functions is primarily inhibition of apoptosis of erythroid precursors [69]. 
Hypoxia is able to increase largely Epo production. Hypoxia regulates Epo and 
consequently erythropoiesis, the down-regulation of hepcidin expression during 
anemia is a consequence not only of hypoxia but also of erythropoiesis itself. In fact, a 
new hormone produced by erythroblasts in response to EPO during erythropoiesis-
erythroferrone- plays a role in hepcidin level reduction [1] (Figure 2).  
Cellular regulation 
Hepcidin is fundamental in the systemic regulation of iron metabolism. Moreover other 
mechanisms exist at cellular level to regulate genes involved in iron metabolism. 
Among these the modulation of general cellular mechanisms that promote alternative 
transcript variants (i.e. alternative transcription initiation, polyadenylation and splicing) 
and more specific systems able to control the stability of the mRNAs and proteins 
involved in iron homeostasis [1].  
 
IRON METABOLISM DISORDERS 
Notwithstanding a perfect regulation in body iron homeostasis, iron overload or 
deficiency conditions could be induced by genetic, physiological or environmental 
factors. In the presence of an iron overload the consequence is the iron deposition in 
liver, heart and other tissues [75]. If the overload is due to increased dietary absorption 
the deposition occur in the liver, with a gradient from the periportal hepatocytes to the 
centrilobular hepatocytes. If iron overload is due to an uncontrolled release from 
macrophages, iron accumulates at mesenchymal level [76]. Iron overload disorders are 
genetic or acquired. Hemochromatosis, aceruloplasminemia, and atransferrinemia are 
genetic disorders with iron overload [76]. Acquired iron loading diseases originate 
from a secondary iron overload not due to mutation in genes involved directly in iron 
homeostasis.  
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Several types of anemia-genetic or acquired- are due to iron deficiency. Iron deficiency 
anemia (IDA), anemia of chronic diseases (ACD) and the iron-refractory iron-
deficiency anemia (IRIDA) are typical iron deficiency pathologies [77-79]. 
Iron overload disorders 
Hereditary hemochromatosis (HH) is the most frequent iron overload disease, show an 
excessive parenchymal iron deposition in several organs, as liver, heart and pancreas. 
All hereditary forms lead to the same pathological mechanism of entry of higher 
amounts of iron to the plasma to support iron-depending processes, i.e. erythropoiesis. 
Higher amounts of iron in plasma induce primarily increased Tf saturation and iron 
deposition at several organs, with long term consequences: cirrhosis, hypogonadism, 
cardiomyopathy, arthropathy, diabetes and hepatocellular carcinomas [80]. In HH 
hepcidin level is abnormally low although high levels of iron in circulation [81-85]. 
HH is divided in four types for clinical outcomes and genes affected: HFE-related HH, 
juvenile hemochromatosis (JH), TfR2-associated hemochromatosis and ferroportin 
disease. The HFE-related HH is the mildest form (90% of total cases of HH), 
characterized by a gradual deposition of iron in organs along life [80]. It is 
characterized by elevated Tf saturation and sFt levels. The majority of the individuals 
with hemochromatosis are actually homozygotes for p.C282Y. This substitution avoid 
the formation of the disulfide bond between C225 and C282 residues, essential for 
HFE association with beta2-microglobulin(β2M) [81]. The hepcidin expression is 
deregulated because p.C282Y mutated HFE protein is unable to bind to β2M and to be 
transported to the cell surface where it would interact with TfR1 and TfR2 [1]. JH is a 
rare disease of iron overload metabolism. It is mainly due to mutations in the HJV and 
HAMP genes [82,83]. It presents a severe iron overload caused by full saturation of Tf, 
high sFt levels and iron deposition [80]. The third type of HH is due to mutations in 
TfR2 gene; characterized by increased TfSat and sFt [80,85]. The last type of HH, also 
named ferroportin disease, is an iron overload disease with mutations in the SLC40A1 
gene. There are two different form of disease: form A- ferroportin mutants are unable 
to export iron from cells leading to cellular (especially macrophage) iron accumulation 
with decreased availability of iron for serum Tf (low saturation level) [80]. Form B: 
ferroportin mutations cause a gain of function with normal iron export capacity but 
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insensibility to hepcidin downregulation, consequently iron is constitutively absorbed 
and released by cells, resulting in increased Tf saturation and parenchymal iron 
overload [84]. Mutations in CP gene generate another rare iron metabolism-related 
disease named aceruloplasminemia. Main symptoms of aceruloplasminemia are brain 
iron deposition, retinal degeneration, ataxia and dementia for its essential role in brain 
iron metabolism [87]. Mutations in Tf gene generate atransferrinemia, a microcytic and 
hypochromic anemia with tissue iron overload, increased sFt and low levels of Tf [88]. 
Aceruloplasminemia and atransferrinemia were rare and recessive disorders. 
Iron deficiency pathologies  
IDA is the most common nutritional deficiency worldwide, frequently occurs in 
premenopausal woman, children, hospitalized individuals or caused by an iron-poor 
diet [89]. Individual with permanent state of inflammation for chronic disease present 
ACD [78]. During inflammation, IL-6, a pro-inflammatory cytokine produced by 
macrophages, induce the expression of hepcidin and, consequently, low dietary iron 
absorption and stored iron release [90] causing anemia. There are also congenital 
anemia disorders; among these, IRIDA, characterized by congenital microcytic and 
hypochromic anemia, low MCV, Tf saturation, no response to iron administration, 
recessive transmission [91]; caused by mutations in the MT2 gene (TMPRSS6) [92]. 
Matriptase-2 physiologically inhibits hepcidin expression causing the cleavage of 
membrane Hjv; IRIDA patients show extremely high levels of hepcidin, consequently 
iron absorption by the gut is impaired [93]. 
  
Introduction 
 
12 
CHAPTER 2 
Dictyostelium discoideum 
 
THE ORGANISM 
Dyctiostelium discoideum (Dd) belongs to the social amoebae (Dictyostelia). 
Phylogenetically, Dictyostelia form a subgroup in amoebozoa, one of the kingdoms of 
eukaryotes [94]. Dd is evolutionarily distant from yeast and humans, at the edge 
between unicellular and multicellular organism, as the name “social” suggest; its 
genome sequencing indicates that is closer to animals and fungi than to plants [95]. 
Dd lives in deciduous forest soil and moldy leaves where feeds on bacteria, yeast and 
other microorganisms that are engulfed by phagocytosis [96]. Normally, during 
vegetative growth stage, Dd grows as a single-cell amoebae independent, using simple 
mitotic divisions for its duplication. If depletion of food occurs (starvation), a 
developmental program started with several changes in gene expression [97]. Cells 
aggregate by chemotaxis, caused by secretion of cAMP. The derived aggregate is 
multicellular, with peculiar differentiation and morphogenetic characteristics (Figure 
3). The microenvironment starvation finally leads to the formation of a fruiting body 
consisting of spore and stalk cells. Stalk cells are dead vacuolated cells, whereas spore 
cells are resistant to extreme temperatures or food scarcity. If favorable environmental 
conditions occur, new amoebae will be born from the spores [94] (Figure 3).  
 
DYCTIOSTELIUM DISCOIDEUM AS ANIMAL MODEL 
Human macrophages and neutrophils are immune cells that recognize, engulf 
pathogens and after destroy them in intracellular vesicles. These leukocytes employed 
chemotaxis to reach pathogens and phagocytosis for eliminate them [98]. These 
behaviors are utilized also by Dictyostelium discoideum, to track and ingest bacteria as 
its food source. Consequently, studies of Dd provide insights into chemotaxis and 
phagocytosis of immune cells with the simplicity of this eukaryotic organism [99]. 
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Figure 3. Stages of the Dictyostelium discoideum life cycle. Upper panel: a typical microscopy 
image of the Dd life cycle; Lower panel: the schematic summary of the life cycle: Free living 
amoebae (A); aggregate due to cells chemotaxis toward cAMP released from neighbor cells 
(B); formation of aggregates with increasing complexity (C, D, E); culmination stage (F); 
fruiting body (G). (images from http://www.ailab.si/supp/bi-visprog/dicty/dictyExample.html). 
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The phagocytosis process starts with the binding of pathogen to receptors on the 
leukocyte membrane; this interaction causes a reorganization of actin cytoskeletal 
components in the cell, resulting in the internalization of the pathogen and the 
formation of a phagosome [100]. This vescicle matures by the fusion with endocytic 
and lysosomal vesicles, shaping the phagolysosome, where the ingested pathogen is 
destroyed. Basic aspects of chemotaxis and phagocytosis are evolutionarily conserved 
between human and simple eukaryotic organisms like Dd [101-103].  
In mammals, phagocytosis by macrophages and neutrophils remove pathogens or 
apoptotic cells. In Dd, the same process is essential for acquiring nutrients from the 
surrounding environment. Many intracellular pathogens elude phagolysosomal fusion 
with the intent to avoid lysosomal destruction [104]. Mammalian macrophages, 
neutrophils, and Dd, show similar molecular components involved in phagocytosis and 
phagosome maturation. These findings suggest that pathogens able to escape killing in 
mammalian phagocytes are also capable to avoid phagocytosis mediated by Dd, 
suggesting common targets in both cell types [99] and the ancient evolution of the 
phagolysosomal apparatus [100,105,106]. Thus, Dictyostelium’s strategies to 
neutralize pathogens are expected to be of general relevance [107]. Consequently, Dd 
has become a model organism for studying how host resists to infection or the 
pathogen escape defense strategies [108]. 
 
DYCTIOSTELIUM DISCOIDEUM: PROFESSIONAL PHAGOCYTE AND 
PATHOGEN HOST 
All eukaryotes, independently from the complexity of the organism studied, show 
similar mechanism in the host pathogen interaction [99,109,110]. Pathogens must 
interfere with the maturation process of the phagosome to survive and to obtain a 
replication niche in the host, in the same phagosome or escaping in the cytoplasm 
[111]. Normally bacteria are ingested by Dd with phagocytosis or macropinocytosis 
with the formation of large vesicles on the plasma membrane. After engulfment in the 
cell, the phagosome or macropinosome fuses with acidic vesicles containing V-H
+
 
ATPase and other vesicles with Nramp1 protein exposed on the membranes [112-115]. 
Many pathogens, i.e. Legionella and Mycobacteria, interfere with the endocytic 
pathway avoiding fusion of the pathogen-containing phagosome with acidic and 
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lysosomal vesicles, enhancing the association with different compartments of the cell, 
such as endoplasmic reticulum [116], mitochondria [117], generating a replication 
vacuole. Legionella, due to massive intracellular growth, produce cell lysis, whereas 
Mycobacteria escape intact cells with non-lytic exocytic mechanism [118]. 
Intracellular survival of pathogens depend also from ion acquisition; i.e. S. 
typhimurium virulence relies on Mg
2+
, Mn
2+
, K
+
 and Zn
2+ 
[119-122]; others bacteria as 
Salmonella, Legionella and Mycobacteria accumulate large amounts of iron, as Fe
2+
 is 
an essential metal for all cells [123-125]. Iron deprivation induces the expression of 
siderophores for iron recovery in pathogens. In order to defeat bacteria, a divalent 
metal transporter-Nramp1-depletes the phagosome of iron exploiting a proton gradient 
[115, 126]. Disruption of Nramp gene augment sensitivity to infection in Dd, 
increasing intracellular growth of Legionella or Mycobacteria. In fact, also mutations 
in this transporter are associated to innate susceptibility to mycobacterial diseases and 
S. typhimurium infection [127-129]. Study in Dd on gene expression of Nramp1 
showed increased intracellular growth of L. pneumophila and M. avium if gene 
inactivation occurs, while L. pneumophila growth is completely inhibited by its 
overexpression [115]. L. pneumophila inhibits the recruitment of the V-H
+
 ATPase in 
vacuoles containing bacteria, without a direct effect on Nramp1 recruitment. Indirectly, 
the absence of the vacuolar ATPase inhibit the proton gradient necessary for iron 
depletion due to Nramp1 [116]. 
 
IRON TRANSPORTERS IN BACTERIAL INFECTION 
Iron homeostasis is fundamental for the resistance to pathogen bacteria in higher 
eukaryotes as in Dd. Iron is necessary for Dd, its deficiency or overload reduce Dd cell 
growth. In mammals like in Dd many genes regulate iron homeostasis. SLC11A family 
includes the two iron transporters, namely natural resistance associated membrane 
protein 1 (Nramp1) and 2 (Nramp2).  
The Nramp family is distributed in evolutionarily different organisms, from bacteria to 
humans [126]. In mammals, Nramp1 (SLC11A1) expression is limited to the 
lysosomal membrane of mature macrophages, granulocytes and monocytes [130] 
DdNramp1, like mammalian ortholog, is expressed only in phagosomes and 
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macropinosomes. The protein derived from transGolgi and is rapidly associated to 
phago- or macropinosomes, and is then recycled from the vesicles after lysosomal 
maturation [115]. Nramp1 is a symporter for H
+
 and divalent metal ions out the 
lysosome; this action removes iron and other metals fundamental for intracellular 
pathogens to activate their virulence genes [131]. Moreover another metal transporter-
Nramp2 (SLC11A2, or DMT1)-is present on plasma membrane of several tissues; 
mutations in the mammal Nramp2 transporter are associated to severe microcytic 
anemia, serum and hepatic iron overload [126,132]. In Dd, Nramp2 is localized as 
membrane protein in the contractile vacuole, which regulates osmolarity. The presence 
in different compartments of Nramp1 and Nramp2 suggests that both transporters 
jointly play a role in iron homeostasis.  
Figure 4. Model for Nramp1 activity in Dyctiostelium discoideum. Nramp1 and the V-H
+
 
ATPase colocalized in phagosomes rapidly after their uptake. The activity of the vacuolar 
ATPase generates a proton gradient in the maturing phagosome that provides the electrogenic 
force necessary for Nramp1 to transport iron or other divalent metals, to the cytoplasm, thus 
depleting bacteria from an essential nutrient element. From Bozzaro 2013[108]. 
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Eukaryotic SLC11A proteins transport Fe
2+
, Mn
2+
and Co
2+
 [131,133], whereas for 
bacterial homologs (MntH subfamily) Mn
2+
 is the main substrate [134,135]. In Dd iron 
is not absorbed with membrane transporters, but it is obtained by destruction of 
phagocyted bacteria and release via Nramp1 from phagosomes to the cytoplasm 
(Figure 4).  
In Dd the V-H
+
 ATPase pumps protons inside the lumen of the contractile vacuole 
[136,137]; moreover the same V-H
+
 ATPase is localized also in phagosomes and 
macropinosomes after phagocytosis [137,115] suggesting that the vacuolar ATPase 
provide the electrogenic potential necessary for transport activity of both Nramp1 and 
Nramp2 [126,131,133]. In Dd, depletion from phagosome of iron via Nramp1 could be 
an efficient mechanism of the host to starve the pathogen for iron. On the contrary, 
pathogen (i.e. Legionella) could prevent co-localization of the vacuolar ATPase 
avoiding acidification of the vacuole, inhibiting Nramp1-dependent iron efflux, even 
favoring iron influx for pathogen benefit [116]. In prokaryotes, three different 
manganese transporters (MntH) are related phylogenetically to the Nramp proteins 
[138], the crystal structure for one of them has been recently determined [139]. 
Homologs of Nramp in yeast, Smf1 and Smf2, transport iron and also manganese, 
whereas a third one, Smf3, probably transports iron from the vacuole to the cytosol 
[140,141].  
Introduction 
 
18 
CHAPTER 3  
SOLUTE CARRIER PROTEINS (SLCs) 
 
Membrane transporters expression is diffused all over the body, greatly in epithelia of 
liver, intestine, kidney, and other organs with barrier functions (brain, testes and 
placenta) [142]. Their presence ensure cellular homeostasis of fundamental substrates. 
Pumps, ATP binding cassette (ABC) superfamily and the solute carrier (SLC) 
superfamily are the main transporter category; pumps and ABC transporters use ATP 
hydrolysis for their (in many cases) uphill transport. SLC transporters are crucial for 
the uptake of small molecules into cells. SLC transporters are mostly facilitative or 
secondary-active; specifically depend on electrochemical gradient to facilitate 
substrates movement across membranes, or on gradients of ion created by ATP-
dependent pumps to transport substrates against its concentration gradient [142]. 
 
MEMBRANE TRANSPORTERS 
Transporters are fundamental for the uptake in cells and organelles of sugars, amino 
acids, nucleotides, inorganic ions and drugs [143]. Their mechanism of function sort 
them in: passive transporters (or facilitated transporters) that permit solute diffusion 
down their electrochemical gradient; active transporters that produce solute gradient 
employing mechanism that supply energy (Figure 5).  
The active transporters are subdivided in: “primary active” transporters, ATP-
dependent, such as ABC transporter family and ion pumps (ATPases). 
Mammalian ABC transporters utilize ATP for the transport of different substances 
(ions, carbohydrates, lipids, xenobiotics and drugs) out of cells or into cellular 
organelles [144]. 
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Figure 5. SLC and non-SLC 
transporters. All transporters 
are expressed in the plasma 
membrane or in intracellular 
compartments. Modified 
Hediger 2013 [143]. 
 
 
Ion pumps use ATP to 
actively pump Na
+
, K
+
, H
+
, 
Ca
2+
 and Cu
2+
 out of cells or 
into organelles (145-147]. 
These pumps also maintain 
electrochemical ion 
gradients across membranes 
that are used by ‘‘secondary-
active’’ ion-coupled transporters to drive uphill nutrients transport across cellular 
membranes. Channels, similar to transporters, permit solute movement down their 
electrochemical gradient [148-151]. Transporters show a fixed stoichiometry of 
ions/solutes per cycle of transport; channels, on the contrary, depend on its open 
probability due to gate control and its conductance (amount of charges per second at a 
given voltage).  
 
SOLUTE CARRIER (SLC) MEMBRANE TRANSPORT PROTEINS 
SLC membrane transport proteins are essential for their physiological functions, such 
as nutrient uptake, ion transport, and waste removal [152]. Membrane transporters play 
a key role in the regulation of small-molecule transport across membranes regulating 
cell’s internal physiology and interaction with the environment [153]. The SLC 
superfamily is the largest group of protein transporters, which includes 456 members in 
the human genome, divided in 52 subfamilies phylogenetically grouped [143]. SLCs 
are localized on the cell surface and in organellar membranes as integral proteins; their 
molecular mass is 40-90 KDa, the aminoacidic sequence range is 300-800 residues 
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[154]. SLCs are principally facilitative transporters and secondary active transporters 
(symporters and antiporters). In the superfamily there is a wide variety of transporters. 
 
SLC nomenclature and classification 
The systematical study of all the genes encoding SLC clarifies their evolution from 
common ancestral genes and permit their classification in subfamily on the basis of 
sequence identity. In the 1990s Matthias Hediger created the SLC gene nomenclature 
system to simplify the characterization of different types of mammalian transport of the 
SLC series [155]. Genes are called using the acronym SLC, followed by a number (i.e. 
SLC11, solute carrier family 11), followed by a letter for subfamily definition ( A is 
used if the family is not subdivided) and a last number defining the single transporter 
gene (e.g., SLC11A1). Transporters are included in a specific family when the 
corresponding protein show at least 20% amino acid sequence identity to other 
members of the same family [143]. About 10% (∼2000) of all human genes are 
transport-related, highlighting the biological significance of transporters in cell 
homeostasis. The SLC families are a significant portion of these genes since that 400 
genes coding for SLCs. 
 
Structural biology of SLCs 
All membrane proteins together correspond to one third of the whole proteome and two 
thirds of all current therapeutic targets; unfortunately the number of structures 
deposited in Protein Data Base is exceptionally small, representing less than 1% of all 
available 3D structures. Hydrophobic segments of integral membrane proteins show 
complicated expression and crystallization. Those crystal structures derived mainly 
from atomic structures of SLC homologs from eukaryotes (i.e. the Drosophila 
dopamine transporter DAT (SLC6A4) [156] and prokaryotes (e.g., the Shewanella 
oneidensis di-/tri-peptide transporter PEPTso (an SLC15 homolog)[157]. These 
structures share sequence identity of ∼30% or more and conserved binding site with 
human homologs, useful models for studying substrate specificity of the human SLCs. 
The SLC members show different structure, consisting of a variety of folds, many not 
related to each other [158]. Leucine transporter (LeuT) and the Major Facilitator 
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Superfamily (MFS) are the most diffuse structure in the human SLCs (Figure 6A and 
6C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Transport mechanism models. In each case, a transporter structure that uses the 
mechanism described is shown in (A,C,E) and transport cycle of the associated transporter are 
shown in (B, D, F): outward-open, occluded and inward-open. Rocker switch. (A) LacY is 
shown in an outward-open bound conformation with the N- and C-terminal halves in green and 
yellow, respectively, and the substrate in red. (B) The substrate binds to a V-shape 
conformation on the extracellular side of the membrane, inducing an intermediate occluded 
state. The substrate is then released from an inverted V-shape inward-open conformation. 
Gated-pore. (C) LeuT in outward-open bound conformation, with the scaffold and bundle 
domains in light and dark blue, respectively, the substrate and ions in red and purple. (D) The 
scaffold domain remains static, whereas the bundle domain undergoes conformational changes 
to bind and release the substrate. The binding site is enclosed by a thin gate (i.e. a salt bridge) 
on the extracellular side, and a thick gate (TM1) on the intracellular side. Elevator. (E) GltPh in 
outward-open bound conformation, with the oligomerization and transport domain represented 
in light pink and magenta, respectively, and the two gates (HP1 and HP2) in gray. The inhibitor 
is shown in red, and sodium ions in purple. (F) The oligomerization domain remains invariant 
while the transport domain moves in a piston-like movement to transport the substrate from the 
extracellular side to the intracellular side of the membrane. Modified Colas 2016[158]. 
 
The MFS model contains 12 transmembrane helices (TM) arranged into two inverted 
structural pseudo-repeats of six TMs. The MFS structure is one of the most diffuse in 
nature, i.e. the glucose facilitative transporters GLUTs/SLC2 and the proton 
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oligopeptide cotransporter family SLC15 display this structure. LeuT structure have 10 
TMs, with 2 five-TM inverted pseudo-repeats, where the first two TMs in each of the 
two repeats (i.e., the ‘bundle domain’) are twisted relative to the three remaining TMs 
of the repeat (i.e., ‘scaffold domain’). The SLC5 family of Na+/glucose transporters 
and the SLC6 family of Na
+
/Cl
-
 dependent neurotransmitter transporters show LeuT 
structure [158]. Knowledge of the structures of membrane proteins could be useful to 
better understand their functional mechanisms. 
 
Functional mechanisms of SLCs  
The SLC transporters utilize different energy coupling mechanisms to mediate 
movement across the membrane; they comprise secondary active transporters, ion 
channels (the ammonium channel SLC42), and other membrane proteins such as 
SLC51B and members from the SLC3 family able to transport only with other SLC 
members (SLC51A and SLC7 members, respectively) creating functional 
heterodimers. Transport by SLC transporters is a dynamic process mainly due to an 
“alternating access” model. In this mechanism, the transporter alternates between 
outward and inward conformations, with several intermediate states (i.e. an occluded 
state, with the binding site not accessible) [158]. Three major types of alternating 
access mechanisms have been described for SLC transporters (Figure 6): -rocker-
switch. The N- and C-terminal halves of the transporter move back and forth from an 
outward facing state to an inward facing state, perpendicular to the membrane. 
Transporters with an MFS structure transport substrates via the rocker-switch 
mechanism, i.e. the E. coli Lactose Permease LacY (Figure 6A and 6B) [159,160]; -
Gated-pore. The binding site is enclosed by two gates [161]. Opening of the outward-
facing gate enables the substrate binding, the substrate release happens in the cell by 
the opening of the second gate in the cytosol. Proteins with LeuT structure utilize this 
mechanism [162-164] (Figure 6C and 6D); -Elevator. The domain containing the 
binding site, namely transport domain, moves along the axis perpendicular to the 
membrane, whereas an oligomerization domain remains inert (Figure 6E and 6F). GltPh 
displays elevator mechanism, is a trimer with different conformations [165-167].  
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Transporters, diseases and pharmaceutical perspective  
There is increasing interest in SLCs because of their genetic link to human diseases; 
190 different SLCs have been found mutated in human disease [168]; more than 400 
SLC genes are associated with human diseases. Moreover, due to the important role of 
transporters in normal physiology and disease, several transporters are fundamental for 
pharmaceutical perspective. In fact transporters could be used as drug targets or as a 
mechanism to help drug delivery to cells and tissues [152]. 
 
THE SOLUTE CARRIER 11 (SLC11) FAMILY 
Members of the SLC11 (Nramp) family transport iron and other transition-metal ions 
across cellular membranes. The natural resistance-associated macrophage protein 
(Nramp) homologs constitute the SLC11 family, proton-coupled transporters that 
facilitate the cellular absorption of divalent metal ions (such as Mn2+, Fe2+, Cd2+, Co2+, 
Zn
2+
, Ni
2+
, and Pb
2+
) [169]. These membrane proteins are present in all kingdoms of 
life with a high degree of sequence conservation [170]. The mammalian SLC11 family 
is comprised of two members, SLC11A1 and SLC11A2. These proteins share 66% 
identity and 82% similarity in amino acid sequence, and are part of the large SLC11 
family of integral membrane proteins expressed in evolutionarily different organisms 
[169]. In general, SLC11 proteins are transporters that employ the proton 
electrochemical gradient as driving force to transport divalent metal ions, in particular 
transition metal ions [11,133,171]. 
 
SLC11A1: Natural resistance-associated macrophage protein 1 (Nramp1) 
SLC11A1 is a 90-100 kDa integral transmembrane protein expressed in the lysosomal 
compartment of macrophages and in tertiary granules of neutrophils. The encoded 
integral membrane protein is composed of 12 predicted transmembrane domains 
(TMD, Figure 7). SLC11A1 is coexpressed with the lysosomal-associated membrane 
protein 1 (LAMP1), a marker of the late endosomes/lysosomes of resting macrophages 
[172]. During the maturation process of the phagosome, both proteins are recruited to 
the phagosomal membrane in particular when stimulated by inflammatory signals 
[173]. The human SLC11A1 gene was localized to the long arm of chromosome2 
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(2q35); polymorphisms in the NRAMP1 gene are associated with various immune 
diseases [126]. NRAMP1 plays a key role in innate resistance against infection 
mediated by intracellular bacteria, its main function is the regulation of 
intraphagosomal metal concentration, in particular of iron and manganese to limit 
microbial survival and replication [169]. Human SLC11A1 shows an expression 
profile analogous to mouse ortholog and was consequently associated to resistance to 
infections of different intracellular pathogens. A single loss of function mutation 
(G19D) in the predicted TM4 of mouse Nramp1 is associated with an augmented 
susceptibility to infections with Mycobacterium, Salmonella, and Leishmania [174]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Secondary structure representation of SLC11A1. Consensus transport signature 
(blue) and DPGN motif (green) are shown in the representation of SLC11A1. The mutation 
(G169D, in red ) in mice leads to infection susceptibility. White numbers in grey cylinders 
indicate the transmembrane regions; black numbers indicate the first and last amino acid of each 
TMD. Modified Montalbetti 2013 [169]. 
 
The role of Nramp1 in innate immunity is a function evolutionarily ancient, since that 
Nramp gene upregulation after infectious stimuli is already present in fish, 
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invertebrates, and plants, and moreover functional data on the amoeba Dictyostelium 
discoideum, an animal model to study professional phagocyte [115]. 
 
SLC11A2: Divalent metal transporter-1 
The other element of the SLC11 family is Nramp2 (SLC11A2, DMT1, DCT1); this 
transporter is ubiquitously expressed, mainly in duodenum, immature erythroid cells, 
brain, placenta and kidney [169]. Nramp2 play a key role in iron absorption at the 
apical membrane of enterocytes [11] following SLC40A1 mediates basolateral iron 
exit in circulation. Moreover Nramp2 is involved also in the iron recycling from the 
hemoglobin destruction after macrophage phagocytosis of senescent erythrocytes 
[169]. Last role of Nramp2 is the iron transport in the cytoplasm, due to its expression 
on endocytotic vesicles during TfR-mediated cellular iron uptake [175]. Nramp2 exists 
in different isoforms, depending on alternative splicing of the 3’-terminal exon; the two 
isoforms show different C-terminal amino acid and an iron response element (IRE) in 
the isoform I -absent in the isoform II- in 3’ UTR mRNA [176]. Nramp2 isoform I is 
mainly on apical membrane of epithelial cells (duodenum, kidney) [68,177], whereas 
isoform II, with a different C-terminus (25 amino acid residues), is predominantly 
involved in iron recycling endosomes [175]. The importance of Nramp2 for iron 
metabolism appears evident since that mutations impairing Nramp2 function cause 
congenital microcytic hypochromic anemia and serum and hepatic overload in human 
[126]. Moreover, in two animal models of iron deficiency, mk mouse [178] and 
Belgrade rat [18], Nramp2 mutations (G185R in TM4) cause a severe iron deficiency 
and microcytic anemia with impaired intestinal iron absorption [18,178]. The 
SLC11A2 gene encodes a protein of 560–570 amino acid, the native SLC11A2 protein 
of 65 kDa, but the transporter expressed in the cell results 90–100 kDa due to a N-
glycosylation, necessary for plasma membrane expression; the predicted SLC11A2 
topology (Figure 8) shows 12 putative TMDs and intracellular N- and C-terminal 
[169]. 
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Figure 8. Schematic secondary structure representation of SLC11A2. Highlighted circles 
shows the locations of known human mutations resulting in microcytic anemia (pink), the 
DPGN motif (green), consensus transport signature (blue), and residues directly involved in the 
transport mechanism of SLC11A2 (yellow). The amino and carboxyl-termini are denoted by 
NH2 and COOH, respectively. White numbers in grey cylinders indicate the proposed 
transmembrane regions; black numbers indicate the first and last amino acid of each TMD. 
Modified Montalbetti 2013 [169]. 
 
Crystal structure of SLC11 transporters 
The determination of the crystal structure of Staphylococcus capitis DMT (ScaDMT) 
in 2014 gives new information about the determinants of ion selectivity; this 
prokaryotic homolog of the SLC11 transporters shows, similar to LeuT, an inward-
facing conformation with a substrate-binding site in the center of the transporter [139]. 
In particular, the first five α-helices are structurally related to the following five α-
helices by a two-fold rotation around an axis in the center of the membrane [162] 
(Figure 9B and 9C). As in LeuT, the first helix of each repeat (i.e., α-helices 1 and 6 in 
ScaDMT) is unwound in the center of the membrane, creating a niche where residues 
interact with transported substrates. Conserved mechanism for transition-metal ion 
selectivity in all SLC11 family and homologs is suggested since mutations of 
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interacting residues affect ion binding and transport in both ScaDMT (37% are 
identical, 59% are homologous to human protein) and human DMT1. Due to functional 
characterization and high sequence homology, bacterial SLC11 homologs share 
structure and substrate specificity with eukaryotic counterparts suggesting similar 
transport mechanisms [139]. The biggest differences are found in their termini, which 
are both longer in DMT1; the 59 additional amino acids on the C terminus encode an 
additional transmembrane helix, for a total of 12 TMD for DMT1 and 11 TDM for 
ScaDMT (structure and topology in Figure 9). 
Figure 9. ScaDMT structure. (a) Ribbon representation of ScaDMT. (b) Topology and (c) 
structure of ScaDMT. The two halves of the protein are in brown and blue, and helix 11 is in 
magenta. Helices are represented as cylinders. In the topology, the bound ion is a grey sphere in 
the metal ion-binding site. The ion is surrounded predominantly by harder ligands along with 
the soft sulfur of Met226. This binding model is valid for all the family members since 
interacting residues are strongly conserved. Modified Ehrnstorfer 2014 [139]. 
 
The binding site is constituted of conserved residues, able to coordinate divalent 
transition metals (Mn
2+
, Fe
2+
, Cd
2+
 and others) but not alkaline earth metal (Ca
2+
, Mg
2+
) 
[132,179]. This is essential because high concentration of alkaline earth metal in the 
duodenum would interfere with the fundamental absorption of Fe
2+
 [171]. This specific 
selectivity for transition metals is due to the presence of an unusual but conserved 
methionine. The evolutionary pressure to maintain the methionine is explained because 
it increases the selectivity for transition metal transport even with the prevalence of 
calcium and magnesium [171].  
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Figure 10. Ion coordination. 
Transition metal ion coordination 
in the binding site. Interactions are 
indicated by dashed lines. 
Modified Ehrnstorfer 2014 [139]. 
 
 
 
 
 
Moreover other residues in the binding site are important for divalent transition metals 
interaction (Figure 10), i.e. Mn
2+
 is coordinated by the carbonyl oxygen of the peptide 
bond linking residues 223 and 224 at the C-terminal end of α-helix 6a; the side chain of 
Met226 of the same helix; and side chains of Asp49 and Asn52 from the near α-helix 1 
(Figure 10); the conserved His233 is implicated in pH regulation and proton transport 
[180,181]. Fe
2+
, Co
2+
, Ni
2+
, Cd
2+
 and Pb
2+
 occupy the same binding site of Mn
2+
; the 
binding of Cd
2+
 and Pb
2+ 
suggests the uptake mechanism for these toxic heavy metals 
[139]. In Figure 11 is described the transport mechanism of ScaDMT. 
 
Figure 11. Transport mechanism.  
Binding of a proton and a transition metal ion to 
a site accessible from the outside is followed by a 
conformational change of the two halves of α-
helices 1 and 6 around a hinge located at the ion 
binding region. The rearrangement closes the 
extracellular pathway and opens an intracellular 
pathway to the ion binding site. Caused by this 
conformational change, the two substrates are 
released into the cytoplasm, and the empty 
transporter returns to its outward facing state. 
Ehrnstorfer 2014 [139]. 
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Structure-function studies of Nramp metal ion transporters 
Electrophysiological studies of SLC11A2 expressed in Xenopus oocytes revealed that 
SLC11A2 is rheogenic and transports a wide range of divalent transition metal ions 
(Cd
2+
, Co
2+
, Cu
2+
, Mn
2+
, Zn
2+
). At physiological membrane potentials (-90 to -30 mV) 
human and rat SLC11A2 display high affinity for Fe
2+
 (K0.5 circa 2 M at pH 5.5) and 
H
+
 (K0.5  circa 1 M) [181]. Kinetic analysis showed that SLC11A2 transports Fe
2+
 
with H
+ 
in a coupled state with a stoichiometry of 1:1. However, uncoupled Fe
2+
 or H
+
 
currents (leak) through SLC11A2 were observed depending on extracellular pH (pHe). 
At neutral pHe, 50 M Fe
2+
 evoked inward currents not accompanied by a H
+
 influx 
[180] suggesting that Fe
2+
 transport is predominantly uncoupled from H
+
 under these 
extracellular conditions. Steady-state and presteady state currents were observed 
following step-changes in membrane potential at pHe 5.5 in the absence of substrates. 
Moreover, acidifying pHe from 7.5 to 5.5 in the absence of Fe
2+
 results in an inward 
current and intracellular acidification in SLC11A2 expressing oocytes [11]. Presteady-
state currents were pH dependent and inhibited in the presence of substrates, such as 
Fe
2+
 [180]. Interaction between Nramp2 and protons generate changes in protein 
conformation and presteady-state currents.  
Site-directed mutagenesis studies of SLC11 homologs highlighted important residues 
for cation transport, situated in different TMDs. Amino acids with particular properties 
(i.e. charges, histidine, and glycine), once mutated, inhibit the transport [126]. The 
TMD1 C-terminal end and adjacent external loop1/2 are important for metal binding, 
uptake, and for proton coupling [126]. Also histidyl residues in TMD6 (Nramp2 
His267, and His272) are essential for metal/proton uptake and proton-dependent 
interactions; mutations at these sites maintain substrate uptake, but separate it from 
proton transport [126]. Also, TMD2 and 4 are implicated in SLC11A2 metal ion 
transport, permeability, and selectivity. A single F227I mutation in TMD4 abolished 
the proton slip through SLC11A2 without effect on metal ion transport [182], whereas 
the I144F mutation in TMD2 inhibited substrate transport and increased slip currents 
[183]. 
ddNramp1 and ddNramp2 showed aminoacidic sequence quite different, while most 
species harboring two or more homologs of Nramp [184]. ddNramp1 belongs, with all 
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metazoan Nramp proteins, to the archetypical Nramp subfamily, whereas Nramp2 is 
closer to prototypical Nramp proteins like aquatic protists, fungi and proteobacteria 
(i.e. MntH Cα subclass) [138,174,184]. Functional studies on ddNramp1 could 
contribute with novel insights on the mechanism of action of the mammalian ortholog, 
whereas similar studies on ddNramp2 could suggest a role of the homologous proteins 
in protists, and help to clarify the possible function of the contractile vacuole in 
divalent metal homeostasis. ddNramp1 and ddNramp2 had different aminoacidic 
sequences and were localized in different intracellular location, but both proteins 
colocalize with the V-H
+
 ATPase, suggesting that divalent metal transport is strongly 
associated to proton transport, as demonstrated in other members of SLC11 family. For 
ddNramp1, iron uptake studies performed with purified phagosomes demonstrated a 
vacuolar-ATPase-dependent transport [115]. Cell lysis and difficulties to obtain 
isolated and functional vacuole vesicles did not permit similar experiments with 
ddNramp2. Aim of this study would be, however, to know if ddNramp2 is involved in 
iron influx or efflux across the vacuole, and to characterize the different metal transport 
specificity and regulation of the two iron transporters of Dyctiostelium discoideum, 
ddNramp1 and ddNramp2. 
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IN SILICO ANALYSES  
All DNA sequences, obtained from NCBI database (www.ncbi.nlm.nih.gov), were 
analyzed with the following bioinformatic tools: 
Homology information    BLAST    
http://blast.ncbi.nlm.nih.gov/Blast.cgi 
 
Alignments     CLUSTAL O          
http://www.ebi.ac.uk/Tools/msa/clustalo/  
 
Restriction enzymes analyses   WEBCUTTER 2.0        
http://rna.lundberg.gu.se/cutter2/ 
 
ORF identification    ORF finder  
http://www.bioinformatics.org/sms2/orf_find.html 
 
Analysis of different codon usage Rare Codon Calculator % Min-Max  
http://www.codons.org/ 
 
SYNTHESIS OF CHIMERIC cDNA  
In order to generate chimeric cDNA: the main coding sequence of the two transporters 
homologs of SLC11 family, namely Nramp1 and Nramp2 of Dyctiostelium discoideum 
(ddNramp1 and ddNramp2) was attached to portion of N-(59 amino acids) and C- 
terminus (19 amino acids) of rat DMT1 (rDMT1) to facilitate the expression of dd 
proteins on the oocyte membrane. Briefly, to create chimeric cDNA the restriction sites 
HpaI at the N-terminus (position +96 and +291 for ddNramp1 and ddNramp2, 
respectively) and NsiI at the C-terminus (position +1533 and +1749 for ddNramp1 and 
ddNramp2, respectively) were inserted by PCR amplification in cDNA coding for the 
transporters in pGEMT plasmid (see Table1 for primer sequences). On the other hand, 
rDMT1 (NP037305.2) in pSPORT-1 was mutagenized by site-directed mutagenesis 
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(Quickchange site-directed mutagenesis Kit, Stratagene Inc., Milan, Italy) with 
overlapping primers to insert the Eco47III site (at position +171) and the NsiI site (at 
position +1713). All restriction enzymes were supplied by Promega (Milan, Italy). The 
chimeric constructs were fully sequenced before cRNA transcription. The resulting 
chimeric protein is illustrated in Figure 12. 
 
Figure 12. Chimeric protein structure. In grey 12 TMD of ddNramp1 or 2, in black the C- 
and N-terminus of rDMT1. For each protein is described the relative position of amino acids 
and “linker” amino acids. 
 
The resulting chimeric Nramp1 (c-Nramp1) in pSPORT-1 vector generate a protein 
with the first 59 amino acids of rDMT1 replacing the 32 residues at the N-terminus of 
ddNramp1 and the 21 C-terminal amino acids replaced by the last 19 amino acid of 
rDMT1. Regarding c-Nramp2, the same N- and C-terminus of rDMT1 replace the first 
97 and the last 46 amino acids of ddNramp2. The particular AT rich sequence of the 
two ddNramp genes require the following conditions for PCR protocol: DNA 50 ng, 
1.25 ng of each primer, dNTPs 0.5mM, 3U of Pfu Taq polymerase , Pfu buffer 10x in 
50 μl final volume. Thermocycling conditions: 1’ initial denaturation; denaturation 
(95°C) 1’, annealing (60°C) 1’, extension (72°C) 3’ for 25 cycles, followed by 5’ of 
final extension (72°C).  
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PRIMER SEQUENCES USED FOR CHIMERIC SYNTHESIS 
pSPORT-1_DMT1_Nsi                    fw 5'-gttgggcctgtcgttcctggactgtatgcattcggtaagcatct-3' 
pSPORT-1_DMT1_Eco47III           fw 5'-tcggccagcctcggtgccagcgctcctgcttacagcaac-3' 
HpaI_ddNramp1                             fw 5’-gcccGTTAACgaaaaccctttaataatagaaagtgg-3’ 
NsiI_ddNramp1                               rev 5’-CACTGCAGAACCAATGCATagaattaaagttttcttgacccattG-3’ 
HpaI_ddNramp2                              fw 5’-gcccGTTAACccatttcaagatagagatagtaatattgg-3 
NsiI_ddNramp2                               rev 5’-CACTGCAGAACCAATGCATccataataataaacaacataaagcaattG-3’ 
Table 1. Primer sequences utilized forsynthesis of chimeric proteins. In capital letter 
different enzyme restriction sites. 
 
MUTANTS OF CHIMERIC Nramp2 
Mutations in c-Nramp2 were obtained by site-directed mutagenesis following 
manufacturer’s instruction. Briefly, 20 ng of the plasmid pSPORT-1 containing the c-
Nramp2 wild type cDNA were amplified with 3U of Pfu Taq polymerase in the 
presence of overlapping primers to insert the mutated codons (Table 2). 
PRIMER SEQUENCES USED FOR c-Nramp2 MUTANTS SYNTHESIS 
Mutant c-Nramp2 A133E                         fw 
                                                                    rev 
5’-tggatccaggtaattgggaaacagatttagaaggtgg-3’ 
5’-ccaccttctaaatctgtttcccaattacctggatcca-3’ 
Mutant c-Nramp2 E137Q                         fw 
                                                                    rev 
5’-ccaggtaattgggcaacagatttacaaggtgggtcaag-3’ 
5’-cttgacccaccttgtaaatctgttgcccaattacctgg-3’ 
Mutant c-Nramp2 A119G                         fw 
                                                                    rev 
5’-aaaattaaaatcatttttaggacctggattatttatatcggtgggatatatgg-3’ 
5’-ccatatatcccaccgatataaataatccaggtcctaaaaatgattttaatttt-3’ 
Mutant c-Nramp2 G125A                         fw 
                                                                    rev 
5’-ctgcattatttatatcggtggcatatatggatccaggtaattg-3’ 
5’-caattacctggatccatatatgccaccgatataaataatgcag-3’ 
Mutant c-Nramp2 S140A                          fw 
                                                                    rev 
5’-gcaacagatttagaaggtggggcaagatttgggtatcaattaa-3’ 
5’-ttaattgatacccaaatcttgccccaccttctaaatctgttgc-3’ 
Mutant c-Nramp2 R141M                        fw 
                                                                    rev 
5’-caacagatttagaaggtgggtcaatgtttgggtatcaattaatgtgggta-3’ 
5’-tacccacattaattgatacccaaacattgacccaccttctaaatctgttg-3’ 
Mutant c-Nramp2 T293V                          fw 
                                                                    rev 
5’-ggttaaatagtgatagtgttatggttgcagttggcatcgttggtgc-3’ 
5’-gcaccaacgatgccaactgcaaccataacactatcactatttaacc-3’ 
Mutant c-Nramp2 T299V/T300V             fw 
                                                                    rev 
5’-ggttgcaactggcatcgttggtgctgtcgttatgccccataatttgtttttacat-3’ 
5’atgtaaaaacaaattatggggcataacgacagcaccaacgatgccagttgcaacc-3’ 
Mutant c-Nramp2 F306Y                          fw 
                                                                    rev 
5’-cactatgccccataatttgtatttacatggtagtgtggtg-3’ 
5’-caccacactaccatgtaaatacaaattatggggcatagtg-3’ 
Mutant c-Nramp2 A133E/E137Q            fw 
                                                                    rev 
5’-ggatccaggtaattgggaaacagatttacaaggtgggtcaagattt-3’ 
5’-aaatcttgacccaccttgtaaatctgtttcccaattacctggatcc-3’ 
Table 2. Different primer sequences used for generating c-Nramp2 mutants. 
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cRNA TRANSCRIPTION  
For cRNA transcription, the cDNA encoding the desired protein cloned into the 
pSPORT-1 plasmid was linearized with NotI, and cRNA synthesized in vitro in the 
presence of Cap Analog 10mM and T7 RNA polymerase 200U. All enzymes were 
supplied by Promega (Milan, Italy). 
 
OOCYTE PREPARATION AND cRNA INJECTION 
Oocytes were obtained from adult females of Xenopus laevis (Envigo, Bresso, Italy). 
The frogs were anaesthetized in MS222 1g/L (tricaine methansulfonate) solution in tap 
water and portions of the ovary were removed through an incision on the abdomen. 
The oocytes were treated with 0.5 mg/ml collagenase Type IA (Sigma, Milan, Italy) in 
ND96 calcium-free solution for at least 30’ at 18°C to remove follicular cells and 
debris. Collagenase activity were stopped with repeated wash steps in ND96 calcium-
free solution and NDE. After 24h at 18°C in NDE, the healthy looking oocytes were 
injected with cRNA diluted in sterile water (0.5g/l), using a manual microinjection 
system (Drummond Scientific Company, Broomall, PA). The oocytes were then 
incubated at 18°C for 3-4 days in NDE before electrophysiological or different 
transport studies. The experiments were carried out according to institutional and 
national ethical guidelines (permit nr. 05/12). 
 
XENOPUS LAEVIS OOCYTE SOLUTIONS  
The oocyte (ND96 and NDE) solutions used during oocyte preparation and cultures 
had the following composition (in mM), ND96: NaCl 96, KCl 2, MgCl2 1, CaCl2 1.8, 
HEPES 5, pH 7.6; NDE: NaCl 96, KCl 2, MgCl2 1, CaCl2 1.8, HEPES 5, pyruvate 2.5, 
gentamicin 250 g/ml. The external control solution for electrophysiological studies 
contained in mM: NaCl or TMACl, 98; MgCl2, 1; CaCl2, 1.8, HEPES or MES 5. The 
final pH values of 5.5 or 7.6 were adjusted with NaOH or TMAOH respectively. The 
external control solution used for XLOs technique is identical but with addition of 
Ascorbic acid 1mM. 
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ELECTROPHYSIOLOGY AND DATA ANALYSIS  
Electrophysiological studies were performed using the two-electrode voltage-clamp 
technique (TEVC, Oocyte Clamp OC-725B, Warner Instruments, Hamden, CT). 
Intracellular glass microelectrodes were filled with 3M KCl and had tip resistances 
between 0.5–4MΩ. Agar bridges (3% agar in 3M KCl) connected the bath electrodes 
to the experimental chamber. The holding potential (Vh) was -40mV. Recording was 
conducted at a fixed voltage. Transport currents were determined by subtracting the 
records in the absence of divalent metal ion (external control solution) from the 
corresponding ones in its presence. Clampex 10.2 (Molecular Devices, Sunnyvale, CA) 
was used to perform the experiments. Data were analyzed using Clampfit 10.2 
(Molecular Devices). Figures and statistics analysis were prepared with Origin Pro 8.0 
(Microcal Software Inc., Northampton, MA). 
 
IMMUNOCYTOCHEMISTRY  
Immunocytochemistry techniques were utilized on oocytes previously tested on TEVC, 
in order to verify the correct expression of the transporters on the plasma membrane. 
Oocytes were washed twice with ND96 and fixed with 4% paraformaldehyde in ND96 
(15’ at 4°C); then washed at RT with ND96 in mild agitation (5’ at RT, 3 times). 
Finally fixed oocytes were included in Polyfreeze tissue freezing medium 
(Polysciences, Eppelheim, Germany) and immediately frozen in liquid nitrogen. 
Cryosections were obtained with a Leica CM 1850 cryostat (thickness 7 µm) and 
preserved at -20°C until tested. Sections were rehydrated with PBS 10’ at RT, 
incubated in blocking buffer (2% bovine serum albumin, BSA (w/v), 0.1% Tween in 
PBS) at RT for 30’, and then over-night at 4°C with the primary antibody, rabbit anti-
c-Nramp1 or c-Nramp2 from Dictyostelium discoideum (polyclonal antisera purified, 
kindly donated by Bozzaro and coworkers), diluted 1:200 in blocking buffer. Samples 
were washed with blocking buffer 5’ for 3 times at RT. Cryosections were then 
incubated with the secondary antibody, 0.5mg/ml diluted 1:250 in blocking buffer 
(CyTM 3-conjugated Goat Anti-Rabbit, Abcam, Cambridge, UK), at RT for 45’ and 
again washed with blocking buffer 5’ for 3 times at RT. Images were observed with a 
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fluorescence microscope Olympus BH2 through a rhodamine filter set 
(excitation/emission filters 550/580nm). Images were acquired with a DS-5M-L1 
Nikon digital camera system. 
 
XENOPUS LAEVIS OOCYTE SMOOTHIE (XLOS) 
XLOS is a powerful technique to study divalent metal transporters (i.e c-Nramp1, c-
Nramp2 or rDMT1 as positive control) expressed in X. laevis oocytes with the 
fluorophore calcein, able to quench in presence of different divalent metal ions (Figure 
13). To verify the divalent metal transport across Xenopus laevis membranes 
expressing c-Nramp1, c-Nramp2 or rDMT1, control oocytes or injected with the 
specific cRNA, were injected with 50 nl of calcein 12.5 M (Sigma-Aldrich, St Louis, 
MO) dissolved in intracellular solution (KCl 130mM, NaCl 4mM, MgCl2 1.6mM, 
EGTA 5mM, HEPES 10mM, glucose 5mM, at pH 7.6) 4 days after cRNA injection. 
Following fluorophore entry, the oocytes were incubated for 1h in external control 
solution at pH 5.5 or pH 7.6 in the presence or absence of MnCl2, FeCl2 and CoCl2 
100M. After 3x wash in ND96, oocytes were crushed in presence of ND96+SDS10% 
and centrifugated 5’ at maximal speed. Clear supernatants were plated and measured 
on a microplate reader Infinite 200 (Tecan Group Ltd., Männedorf, Switzerland) at 
485 nm for excitation, and 535 nm for emission (given the spectrum of the 
fluorophore calcein). The results were obtained in arbitrary units of fluorescence (AU).  
Figure 13. Schematic representation of XLOS technique. An alternative technique to 
evaluate the entry of divalent metal ions across membrane transporters, particularly useful to 
study non-electrogenic transporters. 
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CHIMERIC PROTEINS SYNTHESIS 
First, to characterize the function of iron transporters of D. discoideum, ddNramp1 and 
ddNramp2 has been expressed in X. laevis oocytes using an appropriate expression 
vector. The original proteins ddNramp1 and ddNramp2 resulted in a very low level of 
functional expression when tested with TEVC, not surprisingly since that in D. 
discoideum are not plasma membrane proteins. To increase their expression on plasma 
membrane of oocytes, the N and C-termini of both proteins were replaced with the N- 
and C-termini of rat DMT1. This transporter kindly provided by Marciani and 
coworkers is well expressed in X. laevis oocytes as previously published 
[11,180,185,186], moreover, in our research work it was utilized as positive functional 
control. Electrophysiological characterization require good levels of expression. The 
chimeric protein between rDMT1and ddNramp1 and ddNramp2 has been constructed 
with 59 amino acids at N terminus and 19 residues at C terminus from rDMT1 as well 
as its 3’ untranslated region (UTR) to improve the stability and the expression of D. 
discoideum metal transporters in X. laevis oocytes, with the approach previously 
described for Smf1p [187]. 
 
c-Nramp1 AND c-Nramp2 CODON USAGE ANALYSIS  
To analyze the real feasibility of the heterologous gene expression of Dyctiostelium 
discoideum genes in our model, we applied the software “Rare Codon Calculator Min-
Max” to match the different codon usage utilized by D. discoideum and X. laevis. The 
analysis assign a value “-100%” if the sequence codify only with rare codons, whereas 
“100%” means that the sequence is constituted by common codons; “0%” value is 
attributed if the codon usage is identical to the codon usage of the organism chosen as 
reference. The Figure 14 of c-Nramp1 (left panel) and c-Nramp2 (right panel) showed 
the results of the sequence analysis compared with X. laevis codon usage. The c-
Nramp1 expression in oocytes reaches the min % of -38% in the utilization of rare 
codons indicating that the protein can be translated but with some difficulty; on the 
other hand, c-Nramp2 expression displays a min % of “-43%” suggesting higher 
intrinsic difficulties in the synthesis of this protein. 
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Figure 14 “Rare Codon Calculator Min-Max” analysis for c-Nramp1 (upper panel) and c-
Nramp2 (lower panel) compared to X. laevis codon usage. Red represents the percentage of rare 
codons utilized whereas blue identifies common codons. 
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Dyctiostelium discoideum c-Nramp1 METAL TRANSPORTER: 
ELECTROPHYSIOLOGICAL CHARACTERIZATION  
To characterize the c-Nramp1 metal transporter, the oocytes were tested 
electrophysiologically by TEVC to verify the presence of transport currents associated 
with metal uptake.  
First, oocytes expressing c-Nramp1 were clamped at a fixed voltage (Vh -40 mV) in 
external control Na solution (Figure 15) at pH 5.5 and perfused with different 
concentration (10, 30, and 100M) of MnCl2 and FeCl2 to determine the optimal 
concentration to perform the electrophysiological experiments. FeCl2 and MnCl2 were 
able to elicit inward transport currents also at low concentrations suggesting the high 
affinity of the transporter for these ions (Figure 15). Since that the currents in any 
conditions tested were small, the affinity was not determined with a dose response 
experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Transport current in c-Nramp1. Metal ion transport currents of FeCl2 and MnCl2 
at pH 5.5 in external control sodium solution. Concentration of 10, 30, and 100M for these 
two ions were tested. Experiments conducted at fixed voltage (Vh -40mV).  
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Afterwards, oocytes expressing c-Nramp1 were clamped at a fixed voltage (Vh -40 
mV) and tested in Na (Figure 16A) or in tetramethylammonium chloride (TMA) 
(Figure 16B) solution at pH 5.5 and perfused with different divalent metal substrates 
(Fe
2+
, Mn
2+
, Co
2+
, Cd
2+
, Ni
2+
, Pb
2+
, Zn
2+
, all 100M) to determine ion selectivity. TMA 
was an impermeant cation, and it was used to test the sodium dependence. Both TMA 
and Na gave rise to transport current, suggesting that the transporter is sodium 
independent. 
 
Figure 16. Transport current in c-Nramp1. Metal ion transport currents of 100M for all 
divalent ions tested at pH 5.5. Experiments conducted at fixed voltage (Vh -40mV). A. External 
control sodium solution. Mean+SE of 7-50 oocytes, 2-7 batches. B. External control 
impermeant TMA solution. Mean+SE of 3-25 oocytes, 2-5 batches. Transport currents were 
determined by subtracting the records in the absence of the substrate from the corresponding 
ones in its presence. 
 
The mean of the transport currents in the presence of different divalent cation showed 
that Mn
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TMA solution, and only in sodium solution the same metal ions gave rise to apparent 
outward currents. This discrepancy could be ascribed to the block of the sodium leak 
current (Figure 16B) as explained in the following paragraph.  
The similar currents elicited by FeCl2 or MnCl2 (Figure 15) suggest to use the latter, 
that is not oxidizable, to test the pH dependence of the transporter. As shown in Figure 
17, in c-Nramp1 and rDMT1 expressing oocytes the currents became smaller when pH 
vary from acidic (5.5) to neutral (7.6) pH and, at pH 7.6 for c-Nramp1 the current 
became even outward.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Effects of increasing pH on transport currents of MnCl2 100M. Mean±SE of 8-
20 oocytes, 3 batches. P<0.05 for c-Nramp1 and rDMT1 vs control; P<0.05 for pH 5.5 vs pH 
7.6. Mn
2+
 evoked currents mediated by c-Nramp1 and rDMT1, which are maximal at pH 5.5, 
smaller at higher pH and switch outwardly at pH 7.6 for c-Nramp1.  
 
The absence of outward currents at pH 7.6 in TMA demonstrated that this particular 
behavior may be due to the presence of sodium leak current blocked when the amount 
of protons, that are coupled to metal transport, is reduced and the Na ions available. 
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Figure 18. Effects of pH 5.5 or 7.6 on transport currents of MnCl2 100M in external 
sodium or TMA control solution. The outward current at pH 7.6 showed for c-Nramp1 
disappears if Na is replaced by TMA, suggesting the presence of a Na leak current that is 
blocked by the presence of the divalent metal ion substrate. Mean±SE of 10-50 oocytes , 5-10 
batches. P<0.05 for c-Nramp1 and rDMT1compared to control oocytes or at pH 7.6. Transport 
currents were determined by subtracting the records in the absence of the substrate from the 
corresponding ones in its presence.  
 
This particular behavior of c-Nramp1 in sodium solution was previously observed in 
the yeast Smf1p transporter [187,188]. This kind of current, well described by Nelson 
[189], is due to the block of the high Na
+
 permeation trough the transporter when the 
proton concentration was lower than that required for the best functionality of the 
transporter (i.e. pH 7.6). At pH 7.6 the transport of divalent metal ions is anyway 
coupled to proton, in the absence of substrate (Mn 100M in this case) Na+ pass 
through the transporter in an uncoupled way give raise to a huge current. In the 
presence of the substrate, the tranporter starts to work in a coupled way, transporting 
metal ions and proton generating a transport associated current and reducing the Na
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to its small entity compared to the massive Na
+
 current. Moreover this particular Na
+
 
leak current at pH 5.5 reduced its amplitude due to its competition for the same binding 
site or the same translocation pathway with protons that, in this case, are highly 
concentrated. Subsequently to characterize the permeation property of the transporter, 
we recorded the currents in the presence of external solution, where Na was substituted 
with different cation: Li, K, Rb and Cs at the same concentration (98mM) and in the 
absence of divalent metal substrates at both (5.5 and 7.6) pH (Figure 19 and 20).  
 
Figure 19. Mean leak current at pH 5.5 and pH 7.6. Histograms of the mean value of 
currents of non injected (white bars), rDMT1 expressing (light grey bars) or c-Nramp1(dark 
grey bars) expressing oocytes registered in the presence of different cationic solution at pH 5.5 
(upper panel) or pH 7.6 (lower panel), at fixed voltage (Vh -40mV). The values were 
determined by subtraction of the value of the baseline (value of the current in the presence of 
TMA at pH 7.6) from the values recorded in the presence of different cations. Mean+SE of 5-16 
oocytes derived from 2 batches. 
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Figure 20. Representative traces of currents were recorded at pH 5.5 and 7.6 for non injected 
oocytes (control), rDMT1 and c-Nramp1 expressing oocytes respectively. Oocytes were 
clamped at a constant voltage of -40 mV and perfused with the indicated cations (TMA, 
sodium, lithium, potassium, rubidium, or cesium solution 98 mM).  
 
TMA
7.6
TMA
5.5
 
LiClNaClTMA
7.6
KCl RbCl CsCl
c-Nramp1 
rDMT1
Non inj.
pH 5.5 pH 7.6
50s
5nA
 
TMALiClNaClTMA KCl RbCl CsCl
30s
20nA
TMA
7.6
TMA
5.5
 
LiClNaClTMA
7.6
KCl RbCl CsCl
40s
10nA
 
TMALiClNaClTMA KCl RbCl CsCl
30s
10nA
TMA
7.6
TMA
5.5
 
LiClNaClTMA
7.6
KCl RbCl CsCl
40s
6nA
 
TMALiClNaClTMA KCl RbCl CsCl
30s
8nA
Results 
 
44 
 
The traces recorded at pH 5.5 and pH 7.6 were reported in Figure 20 for non injected 
oocytes (control), rDMT1 and c-Nramp1 expressing oocytes. All recording started 
with TMA at pH 7.6 considering this condition as “zero” currents for subsequent 
analysis of mean currents. 
All the cationic solutions elicited current in all the oocytes tested; in c-Nramp1 oocytes 
at both pH generated currents with mean values of about 100nA (pH 5.5) and 200nA 
(pH 7.6) or even larger. The current amplitude in sodium solution at pH 7.6 was about 
200 nA, and diminished as the pH decrease to 5.5. This behavior showed that sodium 
has a high permeability through the chimeric transporter. In lithium the currents were 
similar at both pH, an uncoupled current of -110 nA was present at pH 7.6 and reduced 
to -90 nA at pH 5.5. When the impermeant TMA solution was perfused, an inward 
current of about -30 nA was recorded at pH 5.5, showing that in the absence of other 
permeating cation the slippage of protons occurs. The same solutions and pH 
conditions tested in oocytes expressing rDMT1 showed an inward smaller (30 to 40 
nA) current at pH 5.5 independently of the perfused solution; this is due to protons 
entering the transporter even in the absence of divalent metal ion, and showed the high 
specificity of the transporter for this substrate. At pH 7.6 the currents were similar to 
control oocyte, confirming that only proton can pass through rDMT1. In control 
oocytes, the acidic pH slightly depolarize the resting membrane potential. This is 
visualized in voltage clamp as an inward current of 2 to 5 nA. Since that rDMT1 didn’t 
show leak current and that the two transporters displayed a different behavior for ion 
selectivity, we evaluated the peculiar ion specificity of c-Nramp1 considering the study 
of Eisenman sequence for equilibrium ion exchange [190], in order to verify if these 
leak currents were due to the transporter itself or to a channel conductance associated. 
Briefly, to discriminate between a channel (weak field strength site) and transporter 
(strong field strength site) must be considered hydratation energy and ion dimension. 
In the case of a transporter, ions can cross the membrane with their acqueous shell, 
and, on the other hand, in the case of a channel, ions diffuse quite freely, not associated 
with acqueous molecules, generating only weak interaction, but in a permeation 
pathway that require specific sites that mimic the hydration shell. Comparing the 
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Eisenman sequence for equilibrium ion exchange with c-Nramp1 selectivity let us 
classify it in the “X Eisenman sequence” where the order of the cation is Na+> Li+> 
K
+
> Rb
+
> Cs
+
, the leak currents presented by the chimeric transporter were typical for 
a “strong interaction site” where ions pass through the transporter itself. On the 
contrary the low sequence number (III Eisenman sequence: Rb
+
> K
+
> Cs
+
> Na
+
> Li
+
) 
of rDMT1 was not due to the transporter itself but to the endogenous channel proteins 
present on the oocyte membrane. In fact, in this transporter, not only the selectivity but 
also the current dimension were similar to control oocytes, where the currents recorded 
in the presence of different cations are surely due to their ion channels. 
 
Dyctiostelium discoideum c-Nramp2 METAL TRANSPORTER: 
ELECTROPHYSIOLOGICAL CHARACTERIZATION 
In contrast to c-Nramp1 and rDMT1, c-Nramp2 did not elicit any measurable transport 
current, either in sodium or in TMA solution, independently from substrates, holding 
potential, and pH of the testing solution (Figure 21). In addition, also in the presence of 
injected divalent metal ion inside the oocyte no currents were recorded. Consequently, 
it was necessary to verify the presence of c-Nramp2 on the membranes of the oocytes 
in order to verify the assumption that c-Nramp2 transporter could be electro-neutral.  
 
 
 
 
 
 
 
 
 
 
Figure 21. Transport associated current in c-Nramp2 expressing oocytes compared to 
control at a fixed potential (Vh -40mV). MnCl2, FeCl2 and CoCl2 tested 100M elicited 
transport associated currents similar to non injected oocytes. 
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IMMUNOLOCALIZATION EXPERIMENTS of c-Nramp1 AND c-Nramp2 
Immunolocalization experiments on cryosections of oocytes were performed to 
evaluate the presence of the two chimeric proteins at the oocyte membrane. Oocytes 
expressing the transporters, as well non injected oocytes, were labeled with a rabbit 
primary polyclonal antisera anti-c-Nramp1 or c-Nramp2 and with a secondary antibody 
anti rabbit Cy3 conjugated.  
 
 
Figure 22. Immunolocalization of c-Nramp1 and c-Nramp2 on oocyte membrane. A-
Immunolocalization experiments on oocytes expressing c-Nramp1; on the left 63x image, on 
the right 10x image; the last image is the control. B- Immunolocalization experiments on 
oocytes expressing c-Nramp2; on the left 63x image, on the right 10x image; the last image is 
the control. Experiments were repeated at least on five oocytes from two batches for each 
condition; controls are oocytes treated as samples but non injected with the cRNA of interest. 
 
Representative images of immunocytochemical experiments are shown (Figure 22). 
The images, that were acquired with fluorescence microscopy (rhodamine filter set 
with excitation 550 and emission 580nm) confirmed the presence for c-Nramp1 
A
B
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and indicated that even c-Nramp2 transporter was well expressed on oocyte 
membranes. 
 
MUTAGENIC STUDY ON c-Nramp2 TRANSPORTER 
With the goal to find the electrogenic determinants of Nramp family, cNramp2 
sequence was compared to different homologs, namely rDMT1, human Nramp2, 
ddNramp1 and scaDMT. The choice of these homologs for the alignment is due to the 
newly described crystallography of scaDMT, to the mutation well described in 
literature of rDMT1 and hNramp2 [126,178] and to the electrogenic activity of 
ddNramp1 characterized in this thesis. The crystallography studies of Ehrnstorfer [139] 
showed that TMD1a, TMD1b, TMD6a and TMD6b transmembrane domains are 
involved in the interaction with the divalent metal substrates or with protons. Thus the 
alignment analysis suggest the creation of mutants of c-Nramp2 in order to obtain 
transporters with a clear electrogenic activity (Figure 23). These mutations were 
located in different but always crucial portion of the transporter. Site directed 
mutagenesis was then applied to create different c-Nramp2 mutants. In particular 
mutations involved in TMD1a were A119G and G125A; in TMD1b were A133E, the 
double mutant A133E/E137Q, E137Q, S140A, R141M; in TMD6a were T293V, the 
double mutant T299V/T300V; in TMD6b was F306Y. 
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Figure 23. 
Alignment of 
different homologs 
of the SLC11 family. 
In yellow all the 
TMDs; in red on the 
sequence of 
ddNramp2 the point 
mutations choosen to 
create all the mutants 
of c-Nramp2 wild 
type.  
rDMT1            --------------------------------------------MGKKQPRAAASAAPNC 16 
hNramp2          ------------------------------------------------------------ 
ddNR1            ------------------------------------------------------------ 
ddNR2            MNNNNNNKKLNKENLNEIENWNEIELTDYKKQGLDEGTSSNIYLFESNGNVVNGSIEDSP 60 
scaDMT           ------------------------------------------------------------ 
 
 
 
 
rDMT1            ELKSYSKSTDPQVSTMVLDPEEKIPDDGASGDHGDSASLGAINPAYSNSSLPHSTGDSEE 76 
hNramp2          ---------------MVLGPEQKMSDDSVSGDHGESASLGNINPAYSNPSLSQSPGDSEE 45 
ddNR1            --------MTPRIESEESAPLVNKNNNNNN-DNNNNNNVDEENPLIIESGIP--IEDLEQ 49 
ddNR2            KQQQQQQQQQQQQQQQQQQQQQQQQNIISSDEEIEDKPFQDRDSNIGDGSDIDSSGDSID 120 
scaDMT           ------------------------------------------------------------ 
 
 
 
 
rDMT1            PFTTYFDEKIPIPEEEY-----SCFSFRKLWAFTGPGFLMSIAYLDPGNIESDLQSGAVA 131 
hNramp2          YFATYFNEKISIPEEEY-----SCFSFRKLWAFTGPGFLMSIAYLDPGNIESDLQSGAVA 100 
ddNR1            KNKPYLIKVPNIDKPDS-----KWINFKTLWAFTGPGFLMSIAYLDPGNLESDIQAGAMA 104 
ddNR2            IENTDYSILVPFEDEENNNGSKSKFSIKKLKSFLGPALFISVGYMDPGNWATDLEGGSRF 180 
scaDMT           -------------------------------------MSVAVGYMDPGNWITSMQGGAQY 23 
 
 
  
 
rDMT1            GFKLLWVLLLAT VGLLLQRLAARLGVVTGLHLAEVCHRQYPKVPRIILWLMVELAIIGS 191 
hNramp2          GFKLLWILLLATLVGLLLQRLAARLGVVTGLHLAEVCHRQYPKVPRVILWLMVELAIIGS 160 
ddNR1            GYQLLWVLFWSTVIGFWLQMLASRLGVVTGKHLAEHCREQYPKTPRLLLWLMTELAIIGS 164 
ddNR2            GYQLMWVLLFSNIMALFLQTLVIKLALVTKNDLAQQCRKEYSKTVNIFLWLILELAIIST 240 
scaDMT           GYTLLFVILISSLAAMLLQSMTVRLGIATGKDLAQMTRHFLSKPVAIIFWIIAELAIIAT 83 
                 *:        : : .: :  :   *            :.   :    .   :   .::   
 
 
 
 
rDMT1            DMQEVIGSAIAINLLSAGRVPLYGGVLITIADTFVFLFLDKYGLRKLEAFFGFLITIMAL 251 
hNramp2          DMQEVIGSAIAINLLSVGRIPLWGGVLITIADTFVFLFLDKYGLRKLEAFFGFLITIMAL 220 
ddNR1            DIQEVIGTAIALQILSNGHIPLWAGVLFTAADTFTFLFLEKYGIRKLEAFFCSLIAIMAI 224 
ddNR2            DLAEVIGTAIGLNILFG—LPL  AGVAITSLDTLLFLAIQRWGIRKLELLILLLLSMITM 298 
scaDMT           DIAEVIGSAIALDLIFG--IPLIVGALITVFDVFLLLFIMRFGFRKIEAIVGTLIFTVLA 141 
                  : :::.:  .: ::      :      :  . : .      .:.: :  .  *:  :   
 
 
 
rDMT1            TFGYEYVTVKPSQSQVLRGMFVPSCSGCHTPQVEQAVGIVGAVIMPHNMYLHSALVKSRQ 311 
hNramp2          TFGYEYVTVKPSQSQVLKGMFVPSCSGCRTPQIEQAVGIVGAVIMPHNMYLHSALVKSRQ 280 
ddNR1            SFGVEYIISKPDQIEVVKGVFIPLCS---QNNISQAVGILGAVVMPHNIYLHSALVQSRE 281 
ddNR2            CFVIELFLSKPIASEVFSGFVPR----LNSDSVMVATGIVGATTMPHNLFLHGSVVKSRK 354 
scaDMT           IFVFEVFISSPQLTDILNGFVPHKEIVTNQGILYIALGIIGATIMPHNLYLHSSIVQSRK 201 
                  :    .                         :     ::*:  :  *  *   :* .   
 
 
 
rDMT1            VNR-ANKQEVREANKYFFIESCIALFVSFIINVFVVSVFAEAFFEKTNEQVVEVCRNSSS 370 
hNramp2          VNR-NNKQEVREANKYFFIESCIALFVSFIINVFVVSVFAEAFFGKTNEQVVEVCTNTSS 339 
ddNR1            IDR-KSETQVKIANKYNRLESAFALIISFIINLLLVSVFAKGFYGETTEIGLSSAAD--- 337 
ddNR2            IPNDRRKSVIKQAYRYNVIDTVLALNCAFFVNIAILMLAASVFWKSNIQVTELSEAYRLL 414 
scaDMT           YDR-HDNEEKAQAIKYATIDSNLQLSIAFVVNCLLLTLGAALFFGT—-KTNDLGGFYDLY 258 
                             :  :  : : : *    .    ::   *   
 
                   
 
rDMT1            PHADLFPNDNSTLAVDIYKGGVVLGCYFGPAALYIWAVGILAAGQSSTMTGTYSGQFVME 430 
hNramp2          PHAGLFPKDNSTLAVDIYKGGVVLGCYFGPAALYIWAVGILAAGQSSTMTGTYSGQFVME 399 
ddNR1            -----FLMDK-----------------YGKVAKYIWAIGLFSAGQCSTMTGTYSGQFVME 375 
ddNR2            TKLMDG-----------------------KLAAVLFGLGLFLAGQSSTITGTMAGQIVME 451 
scaDMT           HALKTEPVLGAT---------------LGGVMSTLFAVALLASGQNSTITGTLAGQIVME 303 
                                                   : . .:: :*    :  *    :    
 
 
 
rDMT1            GFLNLKWSRFARVILTRSIAIIPTLLVAVFQDVEHLTGMNDFLN--VLQSLQLPFALIPI 488 
hNramp2          GFLNLKWSRFARVVLTRSIAIIPTLLVAVFQDVEHLTGMNDFLN--VLQSLQLPFALIPI 457 
ddNR1            GFLKLKIAPWKRLLITRCTAIVPAMVVAILS-TSHLDSLDQWLN--ILQSIQLPFAVVPV 432 
ddNR2            GFIKLRIKPWLRRFITRLLAIIPAAIVIIVLGDKG--TYTLLIISQVLLSIGLPFAVVPL 509 
scaDMT           GFLRLSIPNWLRRLITRSLAVIPVIICLIIFKGNSEKIEQLLVFSQVFLSIALPFSLIPL 363 
                 .: .     :   .:    .  .     ..   .        :            :: *: 
 
 
 
rDMT1            LTFTSLRPVM-SEFSNGIGWRIAGGILVLLVCSINMYFVVVYVQELGHVALYVVAAVVSV 547 
hNramp2          LTFTSLRPVM-SDFANGLGWRIAGGILVLIICSINMYFVVVYVRDLGHVALYVVAAVVSV 516 
ddNR1            LLFTSSEKIMGSKFKNHWLNNQFVRFLSLLIIAINIYLIITFSMQISES-----AWMISI 487 
ddNR2            IIFTSSYEIM-GEFKNRLSIIIINSIIALFIIGLNLATIFQLINDFLHNDSIISKCLTII 568 
scaDMT           QLATSNKKLM-GPFINKTWVNIISWTLIVILSGLNVYLIIQTFQELA---------LEVL 413 
 
                    .:   .:   *            : ::: .::    .                     
 
rDMT1            AYLGFVFYLGWQCLIALGLSFLDCGRSVSISKVLLSEDTSGGNTK----------------592 
hNramp2          AYLGFVFYLGWQCLIALGMSFLDCGHTVSISKGLLTEEATRGYVK----------------561 
ddNR1            VSISFFFYFIFIVYLSMGQENFNS--MTKKIKNLFNNNSNQTYNNINY------------ 533 
ddNR2            FLIPLSIALCCLLLWLIISKINFFTNLLSKIFNNNNNNNNKNIINNNNNYSGNTINNQTIQ629 
scaDMT           FQ-----------------------------------------------------------415 
                                                                              
1a 1b 
2 3 
3 4 5 
5 6a 6b 
7 
8 
9 10 
11 
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IMMUNOLOCALIZATION EXPERIMENTS of c-Nramp2 MUTANTS 
Immunolocalization experiments on cryosections of oocytes were performed to 
evaluate whether the different c-Nramp2 mutants were localized or not on oocyte 
membrane. Oocytes expressing the transporters, as well non injected oocytes, were 
labeled with a rabbit primary polyclonal antisera anti-c-Nramp2 and with a secondary 
antibody anti rabbit Cy3 conjugated.  
 
Figure 24. Immunolocalization of c-Nramp2 mutants on oocyte membrane. 
Immunolocalization experiments on oocytes expressing c-Nramp2 wt and all the c-Nramp2 
mutants synthetized. In order: the negative control (non injected oocyte treated as samples but 
non injected with the cRNA of interest); c-Nramp2 wt and, in order of sequence all the c-
Nramp2 mutants (A119G, G125A, A133E, A133E/E137Q, E137Q, S140A, R141M, T293V, 
T299V/T300V, F306Y ). Experiments were repeated at least on five oocytes from different 
batches; all the images are 50x. 
 
Representative images of immunocytochemical experiments are shown (Figure 24), 
non-injected oocytes were used as negative control but treated as sample. The images 
acquired with fluorescence microscopy (rhodamine filter set with excitation 550 and 
emission 580 nm) suggest that not all mutants seemed expressed on membrane. In 
particular A119G, A133E, the double mutant A133E/E137Q were not expressed at all; 
E137Q, R141M, the double mutant T299V/T300V, and F306Y were expressed at a 
lower extent; whereas G125A, S140A and T293V gave rise to an increased signal. 
Non inj. A119G
A133E A133E/E137Q E137Q S140A
G125A
R141M T293V T299V/T300V F306Y
c-Nramp2 wt
100µm
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Given the overall results of immunocytochemistry we tried, despite the low expression, 
to perform electrophysiological experiments in order to verify the possible 
electrogenicity of c-Nramp2 mutants. 
 
ELECTROPHYSIOLOGICAL CHARACTERIZATION of c-Nramp2 
MUTANTS 
All the mutants created, unfortunately, were not able to generate measurable transport 
associated currents, only the three mutants located in the TMD6 domains-namely 
T293V, the double mutant T299V/T300V and F306Y-elicited very small inward 
currents of 5-10 nA. Consequently, we developed a new method useful to study non 
electrogenic transporters. 
 
DEVELOPMENT OF A NEW METHOD (XLOS) TO DETERMINE 
FLUOROPHORE QUENCING IN OOCYTES  
First the quantification by a microplate reader of the reduction in calcein fluorescence 
(quenching) in the presence of different concentration of divalent metal ions (Fe
2+
, 
Mn
2+
 and Co
2+
) was performed in order to verify the sensibility and the specificity of 
the fluorophore for the planned experiments (Figure 25).  
Figure 25. Dose 
response of calcein 
quenching at 
different pH. The 
results obtained with 
these three different 
metal ions confirmed 
that XLOs method is 
able to detect the 
residual fluorescence 
as other classical 
fluorescence 
technique. 
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The dose response experiments permit to determine at pH 5.5 and 7.6 the K0.5 of the 
three main divalent metal transported by SLC11 family (Table 3) by the application of 
a logistic fitting (Origin 8.0). 
Table 3.K0.5.  
Each experimental condition tested with XLOs was also validated by comparison with 
traditional methods (uptake or TEVC) and confocal microscopy (Figure 26), measuring 
the calcein quenching directly on every single oocytes, confirming its efficacy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Confocal fluorescence quencing. The line “calcein” consider oocyte non 
expressing transporter, the divalent metal ion tested was CoCl2 100M. The ∆fluorescence was 
quantified with ratio FI/F0, where FI was the fluorescence intensity at different time, and F0 
was the fluorescence at time 0. On the left of the figure, confocal series of images were taken at 
the time indicated, at the same condition. 
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Confocal microscopy experiments were conducted only with CoCl2  that is not 
oxidizable, as FeCl2, but with a K0.5 similar, while MnCl2 is quite less able to interact 
with calcein. 
The quantification of the calcein fluorescence with XLOs in non injected oocytes or 
oocytes expressing the transporters in the absence of divalent metal ions were, as 
expected, comparable since that the fluorescence remain stable. Moreover in the 
presence or in the absence of transporter substrates (MgCl2, FeCl2 or CoCl2), calcein 
fluorescence value in oocytes non expressing exogenous transporters was comparable, 
since that divalent metal ions were non-permeating in the absence of transport protein 
on the plasma membrane and consequently did not quench calcein inside the cell. 
We performed XLOs experiment using a different fluorophore in order to confirm the 
general applicability of XLOs also with different transporters, not only SLC11 
homologs. Dextran-FITC (Sigma) is pH sensitive, an acidification inside the oocyte 
quench the fluorophore. Due to this characteristic, we studied oocytes expressing 
Peptide transporter 1 (PepT1). This protein is a proton-coupled cotransporter 
(stoichiometry 1:1, peptide:proton). XLOs technique applied on oocytes expressing 
PepT1 provided results comparable to XLOs technique with calcein fluorophore and to 
traditional techniques (TEVC and confocal microscopy). The percentage of residual 
fluorescence in the presence of GQ 3mM in oocytes expressing PepT1 resulted 
statistically significant compared to controls (Figure 27); (p<0.001 with t-test vs non 
injected oocytes and vs oocytes expressing PepT1 in the absence of substrate; 
mean+SE of 105 oocytes, 7 batches). 
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Figure 27. Dextran-FITC XLOs application. A. Transport associated current recorded with 
TEVC in PepT1 expressing oocytes at a fixed potential (Vh -60mV). GQ 3mM elicited huge 
transport associated current. B. Percentage of residual fluorescence measured with XLOs 
technique. Mean+SE of 105 oocytes, 7 batches (p<0.001 with t-test vs non injected oocytes and 
vs oocytes expressing PepT1 in the absence of substrate). Controls are oocytes non injected 
with cRNA of PepT1, in the absence or presence of GQ 3mM. C. Confocal fluorescence 
quencing. The black line represents non injected oocyte. The green line represents oocytes 
expressing PepT1.The fluorescence variation over time were quantified with ratio FI/F0, FI was 
the fluorescence intensity at different time, F0 was the fluorescence at time 0. D. Confocal 
images were taken at the time indicated at the same condition.  
 
 
All together these preliminary experiments demonstrated the validity, sensibility and 
specificity of XLOs method and support our future results on metal ion transporters 
studied with this new technique. 
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DETERMINATION OF TRANSPORT ACTIVITY IN OOCYTES 
EXPRESSING WILD TYPE METAL TRANSPORTER BY FLUOROPHORE 
QUENCING 
We introduced a new method to detect the uptake of the substrate by monitoring the 
changes in calcein fluorescence due to ion metal interaction with the fluorophore.  
Figure 28. Percentage of residual fluorescence measured with XLOs. Data were reported as 
percentage of residual fluorescence compared to control (non injected oocytes in the absence of 
substrates, fixed at 100%). **p<0.001, *p<0.05 t-test, all transporters vs controls tested with the 
same divalent metal ion at different pH (5.5 and 7.6). Histograms are mean+SE of 75-150 
oocytes, 5-10 batches. 
 
Oocytes expressing different metal transporters were microinjected with calcein, 
incubated with different solutions of divalent metals for one hour, and the resulting 
fluorescence quenching was quantified by microplate reader. XLOs was used to test 
divalent metal ion transport in rDMT1, c-Nramp1, c-Nramp2 expressing oocytes using 
calcein as fluorescence indicator and MnCl2, FeCl2 and CoCl2 as substrates. The 
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quenching action of metals entered in the oocytes by selected SLC11 transporters was 
statistically significant if compared to the quenching results obtained in non injected 
oocytes (Figure 28; **p<0.001; *p<0.05 t-test).  
All the residual fluorescence obtained were calculated as percentage of residual 
fluorescence compared to control (non injected oocytes in the absence of substrates 
considered 100%). In particular in oocytes expressing rDMT1, Fe
2+
 and Co
2+
 induced a 
similar quenching of 75% at pH 5.5 and to a lesser extent also Mn
2+
 (Co
2+
 >Fe
2+
 
>Mn
2+
). At pH 7.6 the metal ions ability to quench the fluorophore was lower to that at 
pH 5.5 (80-85% of residual fluorescence) and with a different capacity between ions to 
quench calcein (Fe
2+
>Co
2+
>Mn
2+
). This data confirmed the electrophysiological 
experiments on that transporter. c-Nramp1 expressing oocytes showed that Mn
2+
 (73% 
of residual fluorescence), Co
2+
(80% of residual fluorescence) and Fe
2+ 
(85% of residual 
fluorescence) at pH 5.5 were transported and were able to quench calcein with ion 
selectivity: Mn
2+
>Fe
2+
 >Co
2+
. At pH 7.6 c-Nramp1 transported Co
2+
>Fe
2+
>Mn
2+
 
ranging from a residual fluorescence of 75% for Co
2+
 to 90% for Mn
2+
.  
Moreover, with this technique we obtained information about c-Nramp2 transporter, 
expressed accordingly to immunocytochemistry results, but not electrogenic. c-Nramp2 
expressing oocytes showed that Fe
2+ 
and Co
2+
(82% of residual fluorescence) were 
transported and were able to quench calcein whereas the transport of Mn
2+ 
was very 
low (94% of residual fluorescence), showing the ion selectivity: Co
2+
>Fe
2+
>Mn
2+
 with 
the last with a poor efficacy to quench calcein at pH 5.5. At neutral pH the transporter 
displayed a different ion selectivity: Mn
2+
 (72% of residual fluorescence)>Fe
2+
 (82% of 
residual fluorescence)>Co
2+
 (85% of residual fluorescence). At pH 7.6 c-Nramp2 
transported divalent metal ions better than at pH 5.5. These data obtained were 
significant for all transporters studied compared to controls tested with the same 
divalent metal ions at different pH (5.5 and 7.6), with the exception for the data of 
Mn
2+
 transported by c-Nramp1 at pH 7.6 and Mn
2+
 transported by c-Nramp2 at pH 5.5, 
that were not significantly different from controls. 
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DETERMINATION OF TRANSPORT ACTIVITY IN MUTANTS OF  
c-NRAMP2 OOCYTES BY FLUOROPHORE QUENCING 
The method XLOs, that we applied to characterize the transporter c-Nramp2 wild type, 
permitted also the analysis of c-Nramp2 mutants. Their expression on oocyte 
membrane were demonstrated with immunological experiments and also with 
electrophysiological experiments, although on T293V, T299V/T300V and F306Y only. 
The low level of expression of c-Nramp2 wild type and of all c-Nramp2 mutants led us 
to perform anyway the XLOs experiments on all mutants, testing also those that 
seemed not present on oocyte membrane with immunolocalization experiments.  
c-Nramp2 mutant 
% residual fluorescence  
pH 5.5 
% residual fluorescence  
pH 7.6 
A119G 84% (100% of WT) 83% (101% of WT) 
G125A 91% (108% of WT) 94% (115% of WT) 
A133E 83% (99% of WT) 86% (105% of WT) 
E137Q 85% (101%of WT) 83% (101%of WT) 
A133E/E137Q 81% (96%of WT) 87% (106% of WT) 
S140A 79% (94% of WT) 83% (101%of WT) 
R141M 90% (107% of WT) 87% (106% of WT) 
T293V 88% (105% of WT) 73% (89% of WT) 
T299V/T300V 65% (77% of WT) 73% (89% of WT) 
F306Y 80% (95% of WT) 78% (95% of WT) 
c-Nramp2 wild type 84% 82% 
 
Table 4. XLOs c-Nramp2 mutants. The percentages described in the table are mean of 2-4 
batches, 15 oocytes utilized in every condition tested. In parenthesis the quenching related to c-
Nramp2 wild type considered 100%. In light blue were evidenced the mutants where the 
residual fluorescence were lower compared to c-Nramp2 wild type. In grey were evidenced the 
mutants that immunolocalization experiments considered not expressed on oocytes membrane. 
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We analyzed the uptake activity with XLOs technique in all of them with the aim to 
obtain data also on electroneutral ones, since that their presence on oocytes membrane 
was already demonstrated with immunolocalization experiments. Oocytes expressing 
different c-Nramp2 mutants, c-Nramp2 wild type or control oocytes were 
microinjected with calcein, incubated in the presence of FeCl2 100 at different pH 
condition (5.5 and 7.6) for one hour, and the resulting fluorescence quenching was 
quantified by a microplate reader. The results were analyzed comparing the percentage 
of residual fluorescence of all the mutants to c-Nramp2 wild type (Table 4). The 
residual fluorescence obtained with T293V, T299V/T300V and F306Y suggested that 
these three mutants were more functional compared to c-Nramp2, although the inward 
currents generated were still little. 
A119G, A133E and the double mutant A133E/E137Q seemed not expressed on 
membrane and neither functional.E137Q and R141M seemed expressed on membrane 
at a lower extent but similar to c-Nramp2 wild type for their functionality. The last two 
mutants, G125A and S140A, were well expressed on oocytes membrane but G125A 
seemed non functional and S140A with a functionality comparable to c-Nramp2 wild 
type. 
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Iron is an element necessary for all the organisms; its role in essential metabolism, 
cellular processes, energy production, biosynthesis is fundamental for life of 
unicellular organism to human. Although being so important, it has harmful properties 
in its free form, in order to neutralize those negative effects, iron need to be linked to 
proteins in the cell. Iron homeostasis is finely regulated at different level and with 
different cells as protagonists: enterocytes absorb iron from food, macrophages recycle 
iron derived from erythrocytes destruction, hepatocytes are the principal storage of 
iron. An imbalance in regulation of iron homeostasis will cause different pathologies 
where iron play a role, for its rise causing iron overload disorders or for its reduction 
giving rise to iron deficiency pathologies [1]. Studies on iron homeostasis, regulation 
and transport could be also done with a simplified model of professional phagocyte and 
pathogen host, Dyctiostelium discoideum (Dd). Dd is a model organism for studying 
how host resists to infection or the pathogen escape defense strategies [108]. Iron 
homeostasis is fundamental for the resistance to pathogen bacteria in higher eukaryotes 
as in Dd. In mammals like in Dd many genes regulate iron homeostasis. Among these, 
genes of SLC11 family, in mammals as in Dd, codify for iron transporters. In 
mammals, Nramp1 (SLC11A1) expression is limited to the lysosomal membrane of 
mature macrophages, granulocytes and monocytes [130]. Dd Nramp1, like mammalian 
ortholog, is expressed only in phagosomes and macropinosomes. Nramp1 is a 
symporter H
+
/divalent metal ions out the lysosome; this action removes iron and other 
metals fundamental for intracellular pathogens [131]. Another metal transporter-
Nramp2 (SLC11A2, or DMT1)-is present on plasma membrane of several tissues; 
mutations in the mammal Nramp2 transporter are associated to severe microcytic 
anemia, serum and hepatic iron overload [126,132]. In Dd, Nramp2 is localized as 
membrane protein in the contractile vacuole, which regulates osmolarity. The presence 
in different compartments of Nramp1 and Nramp2 suggests that both transporters 
jointly play a role in iron homeostasis. 
Our findings about the function of c-Nramp1 and c-Nramp2, in particular, their role in 
divalent metals transport add new insights concerning the mechanism of action of these 
proteins and their mammalian ortholog. 
Discussion 
 
60 
For the characterization of the the iron transporters of Dictyostelium discoideum, 
ddNramp1 and ddNramp2 has been expressed in X. laevis oocytes. These original 
proteins ddNramp1 and ddNramp2 had a very low level of expression, probably 
because these two transporters are not plasma membrane proteins in the social amoeba. 
ddNramp1 and ddNramp2 tested by electrophysiology did not elicit currents of 
sufficient amplitude to characterize the functionality of these transporters. 
Consequently the synthesis of chimeric proteins, where N and C-termini of both 
proteins were replaced with the N- and C-termini of rDMT1, was done to increase their 
expression on the plasma membrane and allowing the functional characterization of 
both transporters. Before starting with the functional studies, we performed an analysis 
of the evolutionary distance between D. discoideum and X. laevis, looking for the 
differences in the codon usage between these two organisms. The codon usage analysis 
predicted problems in the protein synthesis by X. laevis oocytes, due to the utilization 
of rare codons in the original sequence, the rare codon usage in c-Nramp2 was even 
higher than for c-Nramp1.  
The characterization of the c-Nramp1 metal transporter by classical 
electrophysiological recordings, demonstrated the specificity of this transporter for 
divalent transition metals, with maximal inward currents at acidic pH in the presence of 
iron and manganese, confirming the SLC11 family features. FeCl2 and MnCl2 were 
able to elicit inward transport currents also at low concentrations suggesting the high 
affinity of the transporter for these ions. The analysis of the ion dependence showed 
transport currents in the presence of both Na and TMA, indicating c-Nramp1 as a 
sodium independent transporter. The different behavior at neutral pH in the presence of 
substrates when Na or TMA are used as driving ions allowed to observe the presence 
of the sodium leak current. This particular current of c-Nramp1present only in sodium 
solution was also detected in the yeast Smf1p transporter [187,188]. This sodium leak 
current is due to the access through c-Nramp1 in an uncoupled way of the sodium ions 
and give raise to a huge current that diminished drastically in the presence of substrates 
and protons, i.e. when the transporter switches in the “transporter mode”. This peculiar 
sodium leak current is present mainly at neutral pH, whereas the competition for the 
binding site with protons at higher concentration-at acidic pH- reduces its amplitude. 
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This permeation property was compared with rDMT1. This latter didn’t show leak 
current and the two transporters displayed a different behavior for ion selectivity in the 
absence of substrate. We compared the peculiar ion specificity of c-Nramp1 with the 
Eisenman sequence for equilibrium ion exchange [190], in order to verify if leak 
currents were due to the transporter itself or to a channel conductance associated. c-
Nramp1 ion preferences in the absence of substrate can be classified in the “X 
Eisenman sequence” where the order of the cation is Na+> Li+> K+> Rb+> Cs+, 
distinctive of a “strong interaction site” where ions can be consider to pass through the 
transporter itself. On the contrary the low sequence number (III Eisenman sequence: 
Rb
+
> K
+
> Cs
+
> Na
+
> Li
+
) identified for controls (non injected oocytes) and also for 
rDMT1 is typical for a channel like permeation. The absence of leak current and the 
behavior similar to control oocytes, that normally do not express at high level any 
transporter, but only some endogenous channels (especially potassium channels), 
suggest that the sequence of currents recorded in rDMT1 expressing oocytes was not 
due to the transporter itself but to endogenous channel proteins of the oocyte 
membrane. 
Electrophysiological experiments on c-Nramp2, given the higher predicted difficulty 
on oocytes expression suggested by codon usage analysis, conducted us to verify the 
presence of c-Nramp2 on oocytes membranes. Immunolocalization experiments 
confirmed the presence of both the transporters on membrane of expressing oocytes. 
The presence on the plasma membrane, even of c-Nramp2, strongly encouraged the 
assumption that this transporter is electro-neutral.  
With the goal to find the electrogenic determinants of Nramp family, c-Nramp2 
sequence was compared to different homologs. Alignment analysis in order to evaluate 
the degree of conservation of ddNramp1, ddNramp2 with mammalian hNramp2 and 
rDMT1. The analysis showed a high degree of conservation, with some interesting 
differences, which can be evidenced by comparing these proteins with the prokaryotic 
ScaDMT, recently crystallized as model of the SLC11 family [139]. Crystallography 
and functional topology studies [191] show that two symmetrically oriented helics in 
the center of the membrane bilayer, formed by the second half of the first 
transmembrana α-helix are face-to-face with a symmetric half of the sixth α-helix, 
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resulting in the formation of the ion channel and of the substrate-binding site. Different 
residues, fundamental for ion binding and proton co-transport were present in the 
TMD1a, TMD1b, TMD6a and TMD6b, were conserved in all the proteins aligned, 
mammalian Nramp proteins, scaDMT as well as Dyctiostelium counterparts. Literature 
analysis looking for mutations able to affect uptake, substrate specificity, pH 
dependence of transport or leak current [126,133,178,181,185], indicated that only one 
of this site is different between ddNramp1 (C116) and hNramp2 (G208), whereas three 
residues were different in ddNramp2 (A171, E175 and L290) corresponding to E87, 
Q91, G208 in hNramp2. Interestingly, the equivalent mutations E87A, Q91D and 
G208R in rDMT1 result in decreased metal uptake in Xenopus laevis oocytes [133]. 
All these aminoacidic differences could justify results obtained with c-Nramp2, and its 
probable electroneutrality. Therefore we decided to insert mutation in c-Nramp2 in 
order to obtain a protein more similar to ddNramp1 and to other homologs, with the 
goal to restore the electrogenicity. Site directed mutagenesis was then applied to create 
c-Nramp2 mutants. In particular mutations localized in TMD1a were A119G and 
G125A; in TMD1b were A133E, the double mutant A133E/E137Q, E137Q, S140A, 
R141M; in TMD6a were T293V, the double mutant T299V/T300V; in TMD6b was 
F306Y.  
The presence of the mutants on oocytes membrane was verified by 
immunocytochemical experiments. We performed immunolocalization experiments 
with a custom primary antibody polyclonal that could be not able to detect lowest 
protein expression; results should be underestimated. In fact, images suggested that not 
all mutants were well expressed on membrane. In particular A119G, A133E, the 
double mutant A133E/E137Q were apparently not expressed at all; E137Q, R141M, 
the double mutant T299V/T300V, and F306Y were expressed at a lower extent; 
whereas G125A, S140A and T293V gave rise to an increased signal. On the same c-
Nramp2 mutants, despite the low expression or even the apparent lack of expression, 
we performed-anyway-electrophysiological experiments to verify the possible 
electrogenicity of c-Nramp2 mutants synthetized. Unfortunately, only the three 
mutants located in the TMD6 domains elicited very small inward currents. This 
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electrophysiological data suggested that these mutations in TMD6 slightly change c-
Nramp2 wild type behavior. 
All these results underlined the necessity of a different approach to study transporters 
that are electro-neutral. We developed a new assay, named XLOs, which could be 
utilized in substitution to well establish radiolabeled uptake assays. Our novel assay is 
based on calcein (a metal indicator fluorophore) injection into the oocyte and 
quantification of its quenching, as a consequence of imported divalent metals, in every 
single oocyte. 
Each experimental condition tested with XLOs was also validated by comparison with 
traditional methods (uptake, TEVC) and confocal microscopy. XLOs was used to 
verify divalent metal ion transport in rDMT1, c-Nramp1, c-Nramp2 expressing oocytes 
using calcein as fluorescence indicator and MnCl2, FeCl2 and CoCl2 as substrates. We 
demonstrated that the quenching action of metals entered in the oocytes by SLC11 
transporters was statistically significant if compared to the results obtained in non 
injected oocytes. The data obtained with rDMT1 with the application of XLOs 
confirmed the electrophysiological experiments on that transporter; the metal ions 
ability to quench the fluorophore was higher at pH 5.5 (80-85% of residual 
fluorescence) and displayed a different capacity between ions to quench calcein 
(Fe
2+
>Co
2+
>Mn
2+
). Regarding c-Nramp1 expressing oocytes, Mn
2+
 (73% of residual 
fluorescence), Co
2+
(80% of residual fluorescence) and Fe
2+ 
(85% of residual 
fluorescence) at pH 5.5 were transported and able to quench calcein with ion 
selectivity: Mn
2+
>Fe
2+
 >Co
2+
. At pH 7.6 the transport was still present, obtaining 
similar percentages of residual fluorescence although with a different ion selectivity. 
c-Nramp2 expressing oocytes showed that Fe
2+ 
and Co
2+
 were transported and were 
able to quench calcein whereas the transport of Mn
2+ 
was very low, with the last that 
has a poor efficacy to quench calcein at pH 5.5. At neutral pH c-Nramp2 transported 
divalent metal ions better than at pH 5.5 and displayed a different ion selectivity: 
Mn
2+
>Fe
2+
>Co
2+
. 
Until 2016, only two works has been published on the characterization of metal 
transporters in Xenopus oocytes with fluorescent probes, namely to investigate DMT1 
transport using Phen Green SK [192] and our work where the fluorophore was studied 
Discussion 
 
64 
with confocal microscopy in oocytes expressing c-Nramp1, c-Nramp2 and rDMT1 
[193]. All these differences between the two D. discoideum transporters, namely 
ddNramp1 and ddNramp2, should be due not only to structural differences but also to 
the less efficient c-Nramp2 expression in X. laevis oocytes.  
c-Nramp2 mutants expression on oocyte membrane were demonstrated with 
immunolocalization experiments and also with electrophysiological experiments. The 
low level of expression of c-Nramp2 wild type and of all c-Nramp2 mutants suggested 
us to perform XLOs experiments on all mutants, also on those that seemed not present 
on oocyte membrane. The data obtained, together with our previous immunological 
and electrophysiological informations, permitted us to characterize the mutants of c-
Nramp2. In particular, the mutants T293V, T299V/T300V and F306Y, located on 
TMD6, were the only three mutants more functional than c-Nramp2 wild type not only 
considering transport inward currents, but also with XLOs analysis of the residual 
fluorescence. A119G, A133E and the double mutant A133E/E137Q seemed not 
expressed on membrane and neither functional, probably the aminoacidic substitution 
of alanine and glutamic acid to glutamic acid and glutamine, respectively, changed the 
charge distribution of the protein influencing structure and function. E137Q and 
R141M seemed expressed on membrane at a lower extent but similar to c-Nramp2 wild 
type for their functionality. The last two mutants, G125A and S140A, were well 
expressed on oocytes membrane but G125A seemed non functional and S140A with a 
functionality comparable to c-Nramp2 wild type.  
Our data on XLOs, based on fluorophore quenching followed by microplate reader 
analysis, permit us to obtain results from tens of oocytes in different experimental 
condition at the same time, achieving significant statistical data from the same batch 
saving time and animals. In particular, let us to collect data on electro-neutral 
transporters, not suitable to be studied with the classical electrophysiology.  
Data on purified phagosomes of Dictyostelium cells, demonstrated that Nramp1 was 
essential for iron transport, which was imported into the phagosomes at a slightly 
acidic pH if a source of ATP was provided to activate the V-H
+
-ATPase [115]. 
Moreover Nramp1 is also essential in vivo where mediates iron efflux from 
macropinosomes to the cytosol, thus confirming that Nramp1 promote iron depletion 
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from phagosomes [193]. Phagocytosis is fundamental for Dictyostelium cells to engulf 
bacteria, their nutritional source, but also potential pathogenic bacteria [108,193]. 
Dictyostelium Nramp1 displays, therefore, both a nutritive and a protective function, 
favoring accumulation of iron in the cytoplasm upon bacterial digestion and 
simultaneously depriving pathogenic bacteria relegated in phagosomes or 
macropinosomes from an essential element. This peculiar dual role is similar to that of 
the Nramp1 ortholog in mammals macrophages, which recycles iron from ingested 
erythrocytes, while starving ingested pathogens from iron or manganese [135,174]. 
In conclusion, XLOs application permitted also the characterization of ddNramp2. The 
site directed mutagenesis studies helped us to clarify the mechanism of action of 
ddNramp2, suggesting new insights for the study on iron transport across the 
contractile vacuole membrane, where ddNramp2 is expressed, and the function of this 
organelle in the homeostasis of divalent metal in D. discoideum, the animal model for 
phagocytosis and immunological study. 
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Alessandra ed Eleonora. All’inizio la differenza anagrafica mi ha fatto fare 
fatica…..interagire con persone così giovani, conquistare la loro fiducia è stata dura, 
ma alla fine siamo riuscite a diventare un tuttuno, noi, la rana, le iniezioni del venerdì e 
le serate al voltage fino all’ultimo oocita!!! 
 
Alessandra poi nel secondo periodo di dottorato è stata la mia compagna, il lavoro sui 
D-aa è il nostro bambino su cui abbiamo lavorato e riso gomito a gomito…..e poi 
l’arrivo delle chimere, la creazione delle quali mi ha impegnato non poco…..e sulle 
quali abbiamo sudato entrambe!  
 
Sudato anche più del dovuto visto che per un periodo abbiamo dovuto fare a meno 
della super Raffy (Benvenuto Ale!!!)…..che dire di te, sei stata dal mio ritorno post-
Carlotta la persona su cui fare affidamento SEMPRE, al 100%, sia per la scienza che 
per il resto della vita, visto che noi “cinesine” in comune abbiamo tanto……non solo 
l’abito delle spose di Gio, almeno lo spero perchè sei veramente una bella persona e ti 
voglio bene, lo sai anche se non te lo dico mai!!! 
Aknowledgements 
 
 
 
Non posso poi dimenticare SaraHH, senza di te sarei stata ancora lì a fare intestazioni 
imprecando non poco…..GRAZIEEEEEE!!!!! 
 
Paola Campo, mi mancherà la tua super risata, sei sempre positiva e sei una persona 
che non s’abbatte mai, mi hai sempre aiutato e chiarito ogni aspetto genetico nebuloso 
che ti ho sottoposto, grazie! 
 
Le PIRNE….sono sempre stata bene con voi a meno che non sbattessi le 
porte….…..spero di cavarmela così e non dover anche pagare pegno a Betta per le 
consulenze informatiche……Grazie anche a voi per il cammino parallelo al mio, nel 
lab di fianco!!  
 
Non posso nemmeno dimenticare ROSS, senza di te non avrei avuto le foto delle 
immuno…….preziosa più che mai e sempre disponibile….GRAZIE!! 
 
Non posso dimenticare i “nuovi” dottorandi che insieme a me lavorano tutt’oggi, 
Daniele e Francesca, grazie di cuore anche a voi e ai numerosi tesisti passati in 
laboratorio, Deb Tond e Martina nel cuore!! 
 
In ultimo non posso dimenticare chi c’è sempre stato e sempre ci sarà…..almeno spero! 
Adry è la seconda discussione di tesi che ascolti, la prima era pure coi lucidi nel 
lontano Giurassico; spero di essere la tua persona sempre, anche se so bene che è dura 
sopportarmi tutti i giorni. Cerca di condividere con me questo momento e cerca di 
apprezzarmi anche come Dottore di Ricerca in Fisiologia Sperimentale e 
Clinica….visto che questo ho cercato di fare negli ultimi 4 anni, in silenzio, senza 
raccontare troppo…..ma felice per quello che ho fatto, sempre! 
